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Despite achieving significant clinical impact in several major cancer types such as melanoma or 
Hodgkin’s lymphoma, immunotherapies have not had much success in the treatment of pancreatic 
cancer. This cancer is characterised by a pro-inflammatory and immunosuppressive stroma which 
causes aggressive cancer growth and results in drug resistance.  In this study we seek to overcome some 
of the challenges associated with drug delivery into the pancreatic cancer microenvironment and 
design a checkpoint inhibitor therapeutic to inhibit PD1/PD-L1 signalling. Mesenchymal stem cells 
(MSCs) offer an alternative drug delivery method for delivering this treatment to the pancreas due to 
their ability to infiltrate tumours and deliver a therapeutic pay load. In this study soluble PD1 (sPD1) 
variants were generated with increased binding properties to PD-L1. The sPD1 variants were analysed 
using solid-phase protein competition studies as well as live pancreatic cell assays to assess their 
immune checkpoint inhibitory functions. These studies revealed that one variant - expressed as an IgG 
fusion protein, that can completely outcompete wild-type PD1, even at very low concentrations. MSCs 
were then successfully engineered to produce and secrete this variant. These cells were termed 
MSC.sPD1. This way of delivering therapeutics into the tumour microenvironment holds great promise, 
however it should be noted that MSCs have been associated with several undesirable effects, and 












Within the last decade, cancer immunotherapies have truly revolutionized cancer treatment. Unlike 
other mainstream anti-cancer therapies which typically directly target cancer cells, immunotherapies 
target the immune system and the tumour microenvironment (TME) instead (Yu and Cui, 2018). By 
aiding the activation of immune system cells these therapies can promote powerful anti-tumour 
effects. Among these therapies, checkpoint inhibitors -a type of targeted treatment that blocks 
checkpoint proteins on immune cells, have achieved remarkable progress in recent years. Checkpoint 
proteins are receptors which normally regulate the duration of immune responses and maintain self-
tolerance. Blocking inhibitory checkpoint proteins has greatly improved significant outcomes in certain 
cancers such as melanoma (Topalian et al., 2012), Hodgkin’s lymphoma (Ansell et al., 2015) and non-
small cell lung cancer (Borghaei et al., 2015), however immunotherapies have had little success in the 
treatment of pancreatic cancer. This cancer is characterised as very aggressive and with a particularly 
poor prognosis.  Survival rates for pancreatic cancer are less than 5% - one of the lowest among other 
cancers (Pancreatic Cancer UK, 2019). It is the 7th leading cause of cancer death in both males and 
females (Bray et al., 2018). The age-standardised incidence rate of pancreatic cancer in the western 
world has been observed to increase by 1.03% per year between 1973 and 2014 (Saad et al., 2018). 
Epidemiological projections predict that by 2030 it will be the 2nd leading cause of cancer-related deaths 
in USA and Europe after lung cancer, surpassing colorectal, breast and prostate cancer (Rahib et al, 
2014). Taking these worrying statistics into consideration, it is clear that new treatments for pancreatic 
cancer are greatly needed. 
There are several factors which will be reviewed in this paper, that contribute to the poor prognosis 
and treatment outcomes of pancreatic cancer: I) A lack of symptoms and biomarkers in the early stages 
of tumorigenesis, II) A high metastatic tendency during early stages of cancer, III) Drug resistance as a 
result of a dense, fibrous stroma which surrounds the tumour, IV) A highly immunosuppressive TME 
resulting in cancer immune evasion. The aforementioned factors make pancreatic cancer a complex 
and unique disease, making it hard to treat. In our study we seek to overcome some of the current 






1.1. Pancreatic Cancer Progression 
Pancreatic cancer can arise from either endocrine or exocrine cells, however exocrine tumours are 
much more common and make up 95% of cancer cases. Of the exocrine sub-type, it is the pancreatic 
ductal adenocarcinoma (PDAC) that accounts for the majority of the tumours; 90% of all pancreatic 
cancer malignancies are of this type. Pancreatic cancers are tumours derived from epithelial cells in the 
lining of the pancreatic duct. Progression of the disease occurs in a stepwise manner characterised by 
the transition of a normal pancreatic duct to non-invasive precursor lesions which eventually develop 
into an invasive neoplasia (Koorstra et al., 2009). This progression is accompanied by an accumulation 
of genetic mutations which lead to various molecular and morphological changes in cells. Pancreatic 
intraepithelial neoplasia (PanIN) is the most common precursor of pancreatic cancer (Matthaei et al., 
2011) – PanINs are microscopic lesions (<5 mm) which form in the small pancreatic ducts. They are flat 
or papillary and composed of columnar and cuboidal cells containing varying amounts of mucin (Guo 
et al. 2016). 
The early genetic alterations present in PanINs include telomerase shortening, V-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homolog (KRAS) activation and inactivation of tumour suppressor genes cyclin-
dependent kinase inhibitor 2A/cyclin-dependent kinase inhibitor 16 (CDKN2A/16). KRAS mutation is 
present in 90% of pancreatic cancer cases and is one of the earliest genetic abnormalities in the tumour 
progression model for pancreatic cancer and is likely the driver of tumour formation (Löhr et al., 2005). 
The KRAS gene encodes membrane-anchored guanosine triphosphate hydrolase (GTP-ase) and if it 
gains oncogenic activity it causes a continuous induction of downstream signalling pathways 
(MAPK/Erk, PI3K/Akt) contributing to increased proliferative signals, invasiveness and inhibition of cell 
apoptosis. The CDKN2A gene encodes a cell-cycle checkpoint protein which inhibits the cell cycle at the 
G1/S checkpoint by binding to CDKs. Another early genetic abnormality is telomere shortening - 
detected in 90% of PanIN-1 cases compared to the normal ductal epithelium (van Heek NT et al., 2002). 
Telomere shortening results in chromosomal instability, abnormal fusion of chromosome ends and 
gene translocation due to inappropriate chromosome segregation during mitosis which all lead to 
further mutations. Epigenetic changes are also common in early pancreatic cancer and mostly include 
methylation of CpG islands which are present in the promoter regions of genes causing gene silencing. 
Microarray analyses have shown that hypermethylation begins in the early stages of PanINs and 
progressively increases during neoplastic progression (Sato et al., 2008). 
The accumulation of mutational changes leads to progressive molecular remodelling in cancer cells 
causing increasing levels of nuclear and cytoskeletal abnormalities. These changes allow the cancer cells 
to gain the various hallmark properties associated with cancer: sustained cell division, evasion of growth 
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suppression, cell death evasion, replicative immortality, invasion and metastasis abilities, angiogenesis, 
altered cellular metabolism and suppression of immune responses (Hanahan and Weinberg, 2011). 
Ultimately PanINs can develop into an invasive pancreatic cancer, where they push out of the 
epithelium and infiltrate healthy tissue. The primary tumour affects the normal functioning of the 
pancreas by blocking ducts that deliver enzymes to the intestine and by disrupting endocrine gland 
functions thereby causing diabetes and other hormonal disorders. The tumour can also wrap around 
blood vessels and interfere with the function of other nearby organs. The most detrimental effect of 
this cancer however is its proneness to metastasis and the consequent formation of secondary 
tumours.  
1.2. Pancreatic cancer microenvironment 
The pancreatic cancer TME is fairly unique in its characteristics and is characterised by a dense fibrotic 
stroma that surrounds the tumour. At the core of the pancreatic cancer microenvironment lies the 
pancreatic stellate cell (PSC); the key player behind the fibrotic reaction and the remodelling of the 
TME. These normally quiescent cells are characterised by their ability to store retinoids within lipid 
droplets. Normally, they are involved in the regulation of the extracellular tissue matrix (ECM) turnover 
by regulating the synthesis and degradation of ECM proteins (Apte et al, 2012). In response to 
pancreatic injury or inflammation, PSCs activate and undergo morphological changes including the loss 
of retinoid droplets, acquisition of a spindle like shape and increased α-SMA (smooth muscle alpha-
actin) expression (Bachem et al., 1998). Once active, PSCs begin to actively proliferate, migrate and take 
part in a fibrotic reaction where they increase their production ECM components such as collagen type 
I and type II laminin and fibronectin. They also contribute to matrix degradation via production of matrix 
metalloproteinases and their inhibitors (Apte et al., 2004). PSC activation is triggered by several 
interleukins, chemokines, growth factors (GFs) including platelet-derived GF (PDGF), vascular 
endothelial GF (VEGF), transforming GF-β (TGF-β) and tumour necrosis factor alpha (TNF-α) (Korc et al., 
1991; Mews et al., 2002) These factors are present at sites of inflammation which includes tumour 
tissue.  
During pancreatic cancer the pancreas is in a state of chronic pancreatitis which leads to a prolonged 
activation of PSCs and an excessive ECM protein production. The imbalance between ECM deposition 
and degradation causes the formation of a dense fibrotic stroma in a process known as desmoplasia. 
The stromal production is facilitated by an abundance of growth factors. This stroma accounts for a 
large portion of the pancreatic cancer tumour and can make up over 80% of the tumour mass (Erkan 
et al, 2012). A complex cross-talk exists between the stroma and cancer cells which has been shown to 
propagate tumour growth and progression (Figure 1.1.1). Concurrent subcutaneous co-injection of 
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PSCs and cancer cells into immunocompromised murine models resulted in significantly larger and 
more aggressive tumours with a stronger stromal reaction than those produced by an injection with 
cancer cells alone (Bachem et al., 2005). This network of interactions between PSC and cancer cells 
leads to a devastating, self-perpetuating cycle of continuous recruitment and activation of PSCs which 
propagates cancer growth. An increase in the cancer cell population in turn further promotes PSC 
activation. In addition to this, activated PSC cells also take part in autocrine signalling via the secretion 
of TGF, PDGF and connective tissue growth factor (CTGF). These factors cause further perpetuation of 
PSC activation resulting in even more ECM production (Masamune et al., 2009).  
 
Figure 1.1.1 Bi-directional interaction between malignant cancer cells and pancreatic stellate cells (PSCs). 
Malignant cells stimulate PSC activation via secretion of platelet derived growth factor (PDGF), tissue growth 
factor-β 1(TGFβ1) and fibroblast growth factor (FGF). Activated PSCs increase their proliferation and migration 
rates and begin secreting extracellular matrix (ECM) components. PSCs take part in autocrine signalling and drive 
their own activation via the secretion of TGFβ, platelet-derived growth factor (PDGF) and connective tissue growth 
factor (CTGF). Activated PSCs secrete a variety of agents which ultimately aid cancer growth by increasing 
proliferation, motility, metastasis, chemoresistance and decreasing apoptosis in cancer cells.  
Activated PSCs can influence cancer progression via several mechanisms. Firstly, PSCs aid cancer 
metastasis and it has been reported that tumours with an increased number of PSCs have a significantly 
greater incidence of distant metastases (Hwang et al., 2008). This may be due to PSCs involvement in 
epithelial-mesenchymal transition (EMT) of cancer cells - one of the key events during cancer 
metastasis wherein epithelial cells gain mesenchymal-like migratory and invasive properties. When 
pancreatic cancer cells were co-cultured with PSCs, they exhibited loose cell contacts and a scattered 
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fibro-blast like appearance in comparison to mono-cultured cells (Kikuta et al., 2010). The study also 
reported a decreased expression of epithelial markers such as E-Cadherin and β-cadherin and an 
increased expression of mesenchymal markers such as Snail and vimentin. Research also shows that 
PSCs can co-migrate with pancreatic cancer cells to metastatic sites where they are likely to be involved 
in seeding and aiding cancer growth (Xu et al., 2010). Pancreatic cancer cells may also begin to secrete 
the ECM metalloproteinase inducer (EMMPRIN) which causes PSCs to increase secretion of the MMP2 
protein. MMP2 is essential for the degradation of the basement membrane; a critical process during 
cancer invasion. Another important property of PSCs is their ability to prevent apoptosis in cells, further 
promoting the growth of the cancer cell population. Inhibition of apoptosis is thought to be related to 
the up-regulation of anti-apoptotic proteins including Bcl-2, Bcl-xL and survivin in PSCs (Ling et al. 2011).  
As well as aiding cancer growth, the stroma also protects pancreatic cancer cells from therapeutic 
interventions. Despite pancreatic cancer having the same chemosensitivity in vitro as other cancers, 
pancreatic cancer patients have a higher resistance to chemotherapeutics than other cancers 
(McCarrol, 2014). Research points to the dense stroma as the main perpetrator of this resistance. 
Together, the prominent fibrosis and the increasing amount of proliferating cancer cells result in 
growth-induced stress which compresses lymph nodes and blood vessels which leads to an increased 
interstitial fluid pressure (IFP) and hypoxia. An increased IFP impairs drug perfusion and hypoxia further 
drives PSC activation to generate more fibrosis and creates a hypoxia-fibrosis cycle which indirectly 
contributes to chemoresistance by impairing drug delivery to cancer cells (McCarrol et al., 2014). On 
top of this, a state of hypoxia has been shown to induce a number of genes responsible for increased 
invasion, aggressiveness and metastasis of tumours (Chan and Giaccia, 2007). Hypoxia-inducible factor-
1α (HIF-1α) has also been shown to upregulate the multidrug resistance gene which shows a distinct 
mechanism for stromal-induced chemotherapy resistance (Comerford et al., 2002). The secretions from 
PSCs have been also shown to confer a chemoresistant phenotype by supressing H2O2 -induced 
apoptosis (Vonlaufen et al., 2008).  
 
1.3. Immunological responses to tumours 
The immune system also plays key roles in both the positive and negative regulation of pancreatic 
cancer development and progression and the cross-talk between immune and cancer cells is an 
important hallmark of cancer. The immune system employs several strategies to remove malignant cells 
from the body, utilising both the innate and adaptive systems. Several cell types of the immune system 
can recognise ‘danger’ such as pathogens, tumours and damaged tissues. This includes neutrophils, 
macrophages, dendritic cells (DCs), mast cells and natural killer (NK) cells. These cells can offer indirect 
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protection via the removal of viruses, reducing the risk of virally-induced tumours and pathogens, 
resolving inflammation and preventing the establishment of an inflammatory environment which may 
lead to tumorigenesis (Swann and Smyth. 2007). Activated innate system cells can release factors such 
as cytokines – interferons (IFNs), interleukins (ILs) and colony stimulating factors (CSF) – and 
chemokines which can cause local and systemic inflammation and alert the adaptive immune system 
to danger.  The adaptive immune system employs more direct methods of tumour removal by attacking 
tumour cells and causing cell death. Mutations in cancer cell DNA lead to a production of abnormal 
proteins, termed neoantigens. These are processed and presented on the cell surface via the major 
histocompatibility complex (MHC) in a process known as antigen presentation and recognised by 
antigen presenting cells (APCs) such as DCs and macrophages. These cells internalize the neoantigen 
and deliver it to naïve T cells which reside within lymph nodes.  The peptide-MHC complex (pMHC) on 
APCs is recognised by the naïve T cells which bind the pMHC via their T cell receptor (TCR) within an 
immunological synapse. When activated, the naïve T cells differentiate into CD8+ cytotoxic T cells which 
can destroy cancer cells directly and CD4+ Helper T cells which activate B cells and stimulate them to 
differentiate into memory cells and plasma cells and produce anti-tumour antibodies (Wachsmann et 
al., 2013). In addition to TCR stimulation, T cells require an additional signal known as the ‘co-
stimulation’ signal to escape from anergy. Co-stimulatory signals are mostly delivered by the B7 family 
of molecules expressed on APCs (Greenwald et al., 2005). The most important co-stimulatory signal 
comes from CD80 on the APC which binds the CD28 receptor on the T cell and provides the required 
co-stimulation signal required for T cell activation. Together, these signals stimulate proliferation and 
rescue T cells from apoptosis (Chen and Flies, 2013).  
Another member of the B7 family, B7 homolog 1 (B7-H1) (Ishida et al., 1992), was found to engage T 
cells during antigen presentation causing the secretion of IL-10 - an anti-inflammatory cytokine. It was 
therefore proposed that B7-H1 plays a role in the suppression of T cell effector functions. The 
corresponding receptor of B7-H1 on T cells was found to be PD1 and so B7-H1 is now also known as 
PD-L1. Other such negative regulatory signals exist including lymphocyte-activation gene 3 (LAG-3) and 
cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and they have important roles in ensuring self-
tolerance and providing protection against aggravated immune responses. The interplay between 
stimulatory and inhibitory signals determines the overall strength of the signal and thus the level of T-
cell activation. A third signal is delivered by cytokines and regulates T cell differentiation and effector 
capacities. Activation of T cells leads to polarization of the Golgi and granule network and subsequent 
exocytosis of protease-filled granules. Pore-forming proteins assemble to form pore channels called 
perforins on the surface of the cancer cell. These channels allow entry of other proteases, most 
importantly granzymes which are serine proteases that trigger DNA fragmentation - an important 
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characteristic of apoptosis. T cells can also cause tumour death via the activation of the Fas surface 
receptor which leads to pro-apoptotic signalling (Ruddon, 2007).  
At the molecular level, when the TCR recognises the pMHC a complex signalling pathway is initiated 
(Figure 1.3.1). It begins with the recruitment of Src-like tyrosine kinases such as LCK to the signalling 
complex which cause phosphorylation of intracellular chains of TCR and CD28 which recruits ZAP70 to 
CD3/TCR and PI3K to CD28. ZAP70 initiates multiple signalling events via phosphorylation of LAT - a 
membrane adaptor protein, which once phosphorylated binds multiple members of the GRB family of 
adaptor proteins such as GRB2 to facilitate the assembly of macromolecular signalling complexes which 
are necessary for efficient T cell activation. The recruited GRB2 together with SOS protein can now 
activate Ras (Okkenhaug and Vanhaesebroeck, 2003). This leads to the activation of the Raf and MEK 
kinases which ultimately activate the mitogen activated protein kinases (MAPKs) ERK1/2 (Huse, 2009) 
leading to activation of the Fos protein. The co-stimulatory interaction between CD80 and CD28 
reinforces T cell activation signalling. The association of PI3K with the CD28 intracytoplasmic domain 
results in the production of PIP3 (phosphatidylinositosol [3,4,5]-triphosphate) which is required for AKT 
activation; this initiates the AKT-molecular target of rapamycin (mTOR) pathway and rescues T cells 
from anergy. It also stimulates the activation of rel/NF-κβ and Jun nuclear factors. Jun and Fos proteins 
form heterodimers, commonly referred to as AP-1 which is a transcription factor involved in the 
regulation of differentiation, proliferation and apoptosis. PLCγ1 is also activated causing the release of 
Ca2+ ions from the endoplasmic reticulum and NFAT (Nuclear factor of activated T cells) which is 
required for the activation of the expression of PD-L1 (Oestreich et al.,2008). NFAT forms a protein 
complex with AP-1 during TCR activation and CD28 co-stimulation. The use of a NFAT-specific inhibitor 
significantly reduces PD1 expression, and the mutation of the NFATc1 consensus binding site causes 
complete loss of PD1 expression in T cells. Other transcription factors regulating PD1 include Foxo1, 
Notch and IRF9 (Bardhan, Anagnostou and Boussiotis, 2016). The outlined signalling events lead to 
reorganization of the cytoskeleton as well as transcriptional activation of multiple genes leading to T 




Figure 1.3.1. Signalling cascade in T cells resulting from T cell receptor (TCR) ligation with a peptide-bound major 
histocompatibility complex (pMHC), co-stimulated by the CD80 and CD28 interaction. TCR signalling recruits Lck 
which phosphorylates the TCR and recruits Zap70. Zap70 stimulates LAT which activates Grb2 and SOS leading to 
NFAT and Fos activation. PI3K is recruited to CD28 which initiates the Akt/mTOR signalling pathway and activates 
the Jun protein. Fos and Jun form a heterodimer in the nucleus called AP-1 which takes part in downstream 
signalling pathways to regulate proliferation, differentiation and T cell effector function. mTOR signalling also 
regulates growth and survival, motility and protein synthesis. NFAT activates PD1 expression on the surface of the 
T cell. 
1.4. Immunosuppression in pancreatic cancer  
The cancer immunoediting theory states that malignancies are either eliminated, reach equilibrium or 
achieve escape (Dunn et al, 2002). Eliminations occurs when effector immune system cells destroy 
early-stage genetically unstable cells. If the elimination event is unsuccessful the pancreatic cancer cells 
may enter a state of equilibrium where editing occurs. The immune system places a selective pressure 
on cancer cells and any cells with an acquired resistance to this elimination have an advantage. During 
this Darwinian selection, new pancreatic cancer variants emerge with novel mutations which can 
increase the overall resistance to immune attack. During the escape phase tumour cells continue 
proliferating excessively which may eventually lead to malignancies. Cancer cells reduce their 
immunogenicity through various different mechanisms. They may downregulate the expression of MHC 
class I molecules as well as the rate of neoantigen insertion into the MHC groove (Reeves and James, 
2017). Both these actions decrease MHC presentation to T cells. A complete absence of MHC may result 
in full T cell evasion however it also leads to activation of NK cells which are normally inhibited by the 
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MHC (Kambayashi et al., 2001), therefore tumours must employ multiple mechanisms of tumour 
evasion. Tumours can start to secrete a variety of inhibitory cytokines and other small molecules to 
depress the immune system, such as TGF-β which supresses NK and T-cell activation. Another method 
of immune evasion is the acquisition of mutations which switch on certain molecular pathways. Many 
tumours overexpress programmed death-ligand 1 (PD-L1) which, via binding to programmed death 1 
(PD1) receptor on T cells contributes to strong inhibition in T cells. PD-L1 overexpression in tumours is 
often seen as an indicator of progression and poor prognosis in cancer (Escors et al., 2018). 
Pancreatic cancer uses several tactics to effectively hide itself from the immune system, altering the 
immune microenvironment of the tumour in a unique way. Pancreatic cancer exist in an immune 
privileged environment and the proportion of inflammatory cells in murine pancreatic tumours was 
found to rise from 15.5% in normal pancreatic tissue to 50% in tumour tissue (Beatty et al., 2011). 
However, despite this influx of immune cells there is a drastic imbalance in the tumour infiltrate with a 
much higher population of pro-tumour cells than anti-tumour ones (Kunk et al., 2016). Populations such 
as regulatory T cells (Tregs), tumour-associated macrophages (TAMs), myeloid-derived suppressor cells 
(MDSCs), fibroblasts and mast cells are upregulated which ultimately protect tumour cells from being 
eliminated by the immune system and populations of anti-tumour immune cells such as NK cells, DCs 
and CD8+ T cells are downregulated (Kunk et al., 2016) Immune system defects such as this are present 
even in the early PanINs (Hiraoka et al., 2006) indicating that the immunosuppressive nature of TME 
could be a key driver of tumorigenesis. Tregs for example, induce tolerance against neoantigens and 
supress tumour activity of T cells. Disruption of Tregs in murine models correlates with tumour growth 
inhibition (Tan et al., 2009). TAMs express a chemokine C-C motif receptor type 2 (CCR2) which 
mediates tumour proliferation, angiogenesis and chemotaxis of immune suppressive cells to the 
tumour stroma (Mitchem et al., 2013). MDSCs also exhibit specific pathways by which they inhibit the 
immune response and reducing these populations was found to cause tumour regression (Zhang et al., 
2017). In order to develop an effective strategy against pancreatic cancer efforts should be focused on 
increasing the density of effector T-cells within the TME and inhibiting the immunosuppressive cells 
and receptors. Currently, much research is focused on the PD1 receptor due to the powerful inhibitory 
effects it has on immune responses.  
 
1.5. The PD-1/PD-L1 signalling pathway  
PD1 is the cognate receptor for PD-L1. It is a 288-amino acid type I transmembrane protein encoded by 
the PDCD1 gene in humans. It belongs to the B7 family of costimulatory molecules of antigen 
presentation. PD1 is absent on inactivated immune cells but becomes significantly upregulated after 
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activation of cells such as CD4+ and CD8+ T cells, B cells, monocytes, NK cells and DC cells (Agata et al., 
1996). In naïve T cells PD1 expression is induced upon TCR activation and through cytokine receptors 
(Okazaki an Honjo, 2007). PD1 is composed of a single N-terminal immunoglobulin variable region (IgV)-
like domain, a 20-amino acid stalk separating IgV from the plasma membrane, a transmembrane 
domain and a cytoplasmic tail which contains two tyrosine-based signalling motifs (Bardhan, 
Anagnostou and Boussiotis, 2016). Its expression is stimulated by the common γ chain cytokines 
interleukin-2 (IL-2), IL-7, IL-15 and IL-21 (Kinter et al., 2008). PD1 contains an immunoreceptor tyrosine-
based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM) within its 
intracellular domain. ITIM is involved in the recruitment of SH2 domain -containing phosphatases and 
ITSM is necessary for the inhibitory function of PD1 (Neel et al., 2003). 
The ligands of PD1 (PD-L1 and PD-L2) are type I transmembrane glycoproteins that adopt an 
immunoglobulin structure with an IgV distal region and an Ig constant (C) proximal region in its 
extracellular domain. They are anchored to the cell membrane via a hydrophobic transmembrane 
sequence followed by a short cytoplasmic region (Escors et al., 2018). PD-L2 expression is limited to 
professional APCs; it can be found on activated DCs, macrophages and bone marrow derived mast cells. 
PD-L1 is constitutively expressed on T and B cells, macrophages, DCs, mesenchymal stem cells (MSCs) 
and bone marrow-derived stem cells (Yamazaki et al., 2002) and widely expressed on non-
hematopoietic cell lines such as lung cells, neurons, astrocytes, pancreatic islets or fibroblastic reticular 
cells. Additionally, PD-L1 is upregulated in many cell types, including cancer cells by several pro-
inflammatory stimuli. In peripheral tissues, the immunosuppressive activity of PD1 is primarily mediated 
by PD-L1 interactions (Tsushima et al., 2007). Pro-inflammatory cytokines activate signalling cascades 
which cause transcription factor binding to the PD-L1 promoter. IFN-γ for example, activates the Janus 
kinase (JAK) and signal transducer and activator of transcription (STAT) pathway causing transcriptional 
activation of interferon regulatory factor 1 (IRF1) which binds to the PD-L1 promoter. TNFα and IFN-γ 
also activate the NF-κB pathway which can transcriptionally activate PD-L1. Due to these pathways, high 
PD-L1 expression levels are associated with inflamed tissues. Up-regulation of PD-L1 can also be caused 
by epidermal growth factor receptor (EGFR) (Okita et al., 2017), hypoxia-inducible factor alpha (HIF-1α) 
(Noman et al., 2014) and signalling pathways such as MAPK (Gong et al., 2011) and PI3K signalling 
pathway (Parsa et al., 2007).  
Most crystallization studies of the PD1/PD-L1 complex report a 1:1 stoichiometry. Interestingly 
however, free PD-L1 was observed to form homodimers in several crystal structures, wherein the PD-
L1 molecules form an asymmetrical unit (Lin et al., 2008; Chen et al., 2010). The dimeric binding of the 
PD-L1 molecules was found to create a rotating angle and occur via eight hydrogen bonds (Chen et al., 
2010). Out of the known structures of B7 family, B7-1 forms a dimer in crystalline and solution state 
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(Ikemizu et al., 2000) and B7-2 exists as a dimer in CTLA-4/B7-2 complex but as a monomer in a free 
state (Zhang et al., 2003). It is therefore possible that the dimerization of PD-L1 is simply an evolutionary 
relic, however it may serve a functional purpose. The dimerization of the B7 members for example may 
be favoured on the T cell/APC interface as the two-dimensional arrangement of the molecules on the 
cell surface promotes oligomerization by decreasing the entropic penalty compared to when random 
distribution of individual B7 molecules (Zhang et al., 2003). These findings suggest that PD-L1 could be 
forming similar homodimers at the cell surface, however no experimental cell data exist to support the 
hypothesis as of yet. It is theorized that such a homodimer arrangement may not be possible due to 
the predicted glycosylation of the extracellular domains of PD-L1 which may create conformational 
clashes (Zak et al., 2015) however the dimerization theory cannot be ruled out and should be 
investigated further as it may provide a novel way of looking at binding of PD1 and PD-L1. 
PD1 activation inhibits TCR-mediated signalling through dephosphorylation of proximal signalling 
molecules downstream of TCR (Figure 1.5.1). This impairs two important signalling cascades – the 
PI3K/Akt pathway and the Ras/Mek/Erk pathway, both of which are required to initiate T cell activation 
(Arasanz et al., 2017). Engagement of TCR causes the ITIM and ITSM motifs on the cytoplasmic tail of 
PD1 to become phosphorylated which leads to recruitment of SHP-1 and SHP-2 phosphatases to the 
intracellular domain (Chemnitz et al., 2004). TCR engagement with pMHC is sufficient for SHP 
recruitment, however PD1 must also be stimulated in order for T cell suppressive effects to occur. Upon 
PD1 stimulation, SHP begins to dephosphorylate the TCR signalling molecules – CD3, ZAP70 and PI3K 
kinases which results in downstream deactivation of their signalling targets. PD1 can also supress T cell 
activation through indirect pathways by affecting T cell proliferation. The TCR signal causes an increase 
in CK2 kinase expression which phosphorylates the regulatory domain of PTEN which in turn decreases 
its phosphatase activity over PIP3 which is produced by PI3K. When PD1 is engaged, CK2 kinase 
expression is downregulated and PTEN can terminate the PI3K activities. This causes inhibition of the 
mTOR/Akt signalling pathway and results in T cells with lower proliferation and survival and higher 
proneness for apoptosis. SHP recruitment also causes activation of basic leucine transcription factor 




Figure 1.5.1. PD-L1/PD1 signalling causes dephosphorylation of downstream signalling molecules of T cell 
receptor (TCR) signalling thus inhibiting TCR signalling effects. PD1 activation recruits SHP2 which 
dephosphorylates Ras, Zap70 and PI3K, preventing their signalling pathways. This results in the inhibition of 
Akt/mTOR pathway and decreased production of Fos, NFAT and Jun transcription factors which activate genes 
involved in proliferation and cell survival. SHP2 also activates BATF which impairs T cell proliferation and cytokine 
secretion. Ultimately, PD1 signalling in T cells leads to an inhibition of their effector functions.  
It has been observed that PD-L1 co-stimulation contributes to ligand-induced TCR down-modulation on 
CD8+ T cells (Karwacz et al., 2011). The details of this mechanism are not yet well-defined; however, 
most studies point to E3 ubiquitin ligases (especially CBL-B, c-CBL and ITCH) of the CBL family as the 
main mediators of this process. The CBL-B and ITCH E3 ubiquitin ligases have been shown to cause 
ubiquitination of CD3 and CD28 chains thus preventing their phosphorylation and association with the 
signalling kinases ZAP70 and PI3K (Fang and Liu, 2001). Interactions between PD1 and PD-L1 during 
dendritic cell presentation to T cells causes strong upregulation of CBL-b and c-CBL which contributes 
to antigen induced TCR down-modulation. It is very likely that this process also occurs in cancers. T cells 
that overexpress PD-L1 typically also have a low expression levels of surface TCR.  
When T cells become activated, they undergo changes to their metabolism to cover the high energy 
requirements. Quiescent T cells generate energy by using glucose, fatty acids and amino acids to fuel 
oxidative phosphorylation. Once activated, they undergo metabolic reprogramming where oxidative 
phosphorylation still occurs, but aerobic glycolysis becomes the dominant form of metabolism. PD1 
engagement causes a suppression of oxygen uptake and impairs the T cells ability to utilise glycolysis 
and instead promotes the use of fatty acids in beta-oxidation (Patsoukis et al., 2015). On top of this, 
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when T cells are stimulated during PD1 ligation, accumulation of polyunsaturated fatty acids occurs 
which are known to be suppressors of T-cell immunity. Therefore, another way PD1 may alter T-cell 
differentiation is by preventing T cells from appropriately remodelling their metabolism. As a result of 
these metabolic changes there is an increase in the T cell production of reactive oxygen species (ROS) 
derived from fatty acid oxidation (Tkachev et al., 2015). ROS is a harmful by-product of metabolism and 
is known to facilitate various harmful effects such as DNA damage. Therefore, the elevation of ROS and 
subsequent ROS-mediated DNA damage may be aiding cancer cells to acquire more mutations. 
Furthermore, ROS also have important roles in the regulation of the immune response during tumour 
development. More specifically, they greatly contribute to the inhibitory activities of tumour-induced 
immunosuppressive cells (Chen et al., 2016).  
1.6. PD1/PD-L1 signalling in cancer 
When T cells detect neoantigens presented by APCs, activation-induced regulatory receptors, including 
PD1 are expressed on their surface. TCR signalling on activated T cells leads to the production and 
secretion of inflammatory cytokines - the most potent of these being IFN-γ. Cytokines amplify the 
immune response attracting other immune system cells such as NKs and macrophages. They also lead 
to the expression of immunosuppressive factors including PD-L1 on stromal cells in the cancer 
microenvironment and immune system cells such as macrophages and myeloid suppressor cells 
(Spranger et al., 2013). This is an adaptive process which exists to limit immune and inflammatory 
responses. However, this process can cause PD-L1 upregulation in cancer cells too, in a process termed 
‘adaptive immune resistance’ (Figure 1.6.1). In order for cancer cells to upregulate PD-L1 expression on 
their surface, a mutational event must first occur which changes cell-intrinsic mechanisms and results 
in altered activation of signalling pathways. The expression of PD-L1 on tumour cells can be facilitated 
via several mechanisms. Abnormalities in signalling pathways caused by oncogenic events such as 
activation of EGFR, MAPK or PI3K-Akt pathways and elevated STAT3 expression can upregulate PD-L1 
expression in various cancers via transcriptional or post-translational mechanisms (Boussiotis, 2016). 
Amplifications of chromosome 9p24.1 cause increased gene dosage of PD-L1 and PD-L2 together with 
JAK2 in nodular sclerosing Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma (Green 
et al., 2010). Recent studies also indicate that PD-L1 upregulation could be induced by radiotherapy; 
irradiation increased PD-L1 expression on tumour cells and myeloid-derived tumour suppressor cells 
(MDSC) and therefore supressed radiation-induced immune responses (Deng et al., 2014). The 
occurrence of these mutations and expression of PD-L1 by cancer cells interferes with TCR signalling on 




Figure 1.6.1. Adaptive immune resistance in cancer. Cancer cells produce neoantigens which are presented by 
antigen presenting cells (APC) via their major histocompatibility complex (MHC). T cells recognise the neoantigen 
with their T cell receptor (TCR) which leads to T cell activation. Activated T cells begin to express PD1 and secrete 
IFN-y. IFN-y induces PD1 ligand (PD-L1) expression in cancer cells, stromal cells and immune system cells such as 
macrophages and myeloid suppressor cells. Stimulation of PD1 on T cells causes inhibition of TCR signalling and 
leads to lower proliferation, cell survival and cytokine secretion and higher levels of apoptosis. On regulatory T 
cells (Tregs) which are immunosuppressive and inhibit T cell effector functions, PD1 signalling causes increased 
proliferation and cell survival. Both of these effects lead to increased immunosuppression in the tumour 
microenvironment and create a permissive environment for tumour immune evasion.  
The expression of PD-L1 in the tumour and surrounding cell types causes inhibition of T cell functions 
which clearly aids cancer progression by allowing tumour immune escape. On top of this recent 
research implies that PD1/PD-L1 may also have regulatory functions in Tregs and since Tregs are 
immunosuppressive by nature, their aggregation in PD-L1 positive cancers exacerbates the already 
highly immunosuppressive cancer microenvironment. The involvement of the PD1/PD-1 pathway in 
Tregs has not been fully clarified yet, however it has been demonstrated that PD-L1 can induce Treg 
development in vitro and enhance their immunosuppressive functions. PD-L1 has been observed to 
convert naïve CD4+ T cells to Tregs via downregulation of Akt, mTOR and ERK2 and simultaneous 
upregulation of PTEN (Francisco et al., 2009).  Another study evaluated Tregs in Melanoma patients 
receiving anti-PD1 therapy and reported that in responding patients Tregs exhibited decreased 
inhibitory activities (Woods et al., 2018). This suggests that PD1/PD-L1 inhibitors may exert their effects 
on Tregs as well as T cells and provide an alternative pathway of decreasing immunosuppression within 
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the TME. These findings indicate that anti-PD1/PDL1 therapy could be very beneficial in pancreatic 
cancer which has high population of Tregs.  
1.7. Targeting the PD1/PD-L1 signalling pathway in cancer 
Blocking PD1/PD-L1 interactions has been shown to be a very promising therapeutic strategy for PD-L1 
positive cancers, and there are already several anti-PD1/PD-L1 therapies available for clinical use. Many 
studies have shown that systemic administration of PD-L1/PD1 blocking antibodies results in improved 
anti-tumour capacities of T cells (Hirano et al., 2005). Since 2012, PD-L1/PD1 blockade therapies have 
proven effective in the treatment of several human cancers. The first anti-PD-L1/PD1 agents to be 
approved by the FDA were Pembrolizumab and nivolumab - human monoclonal antibodies (mAbs) 
which target the PD1 receptor and prevent PD-L1/PD-L2 binding. Since then, other PD-L1/PD1 blocking 
mAbs have been approved for clinical use, including: atezolizumab, durvalumab and avelumab (Arasanz 
et al., 2017), which target PD-L1. PD1/PD-L1 checkpoint inhibitors have now been approved for the 
treatment of nine malignancies ranging from classical Hodgkin lymphoma to head and neck squamous 
cell carcinoma (HNSCC) (Balar and Weber, 2017) and significantly improved the survival of patients. 
Targeting PD1 has been especially effective in the treatment of advanced melanoma. With the use of 
checkpoint inhibitor therapies such as this one, the survival rates of melanoma patients have drastically 
improved over the past decade (Luke et al., 2017). 
Despite the effectiveness in certain cancers, anti-PD1/PD-L1 therapy has not been successful in the 
context of pancreatic cancer. Until recently the poor effectiveness of anti-PD1/PD-L1 mAbs therapy in 
pancreatic cancer was accredited to a low expression of PD-L1 in this cancer. However, analysis of PD-
L1 mRNA expression in 453 clinical pancreatic cancer samples revealed that PD-L1 expression was 
upregulated in 19% of the analysed pancreatic cancer cases. (Birnbaum et al., 2016). PD-L1 upregulated 
cancers displayed a profile of T cell exhaustion and were enriched in inhibitory molecules with pro-
tumour populations present – Tregs and MDSCs. Anti-PD1/PD-L1 therapy therefore has the potential 
to be an effective way of treating PD-L1 positive pancreatic cancers. Anti-PD1/PD-L1 therapy would re-
activate the exhausted T cells in the TME and may decrease the inhibitory activities of Tregs. As the 
frequency of CD8+ T cells in pancreatic cancer is fairly low, to optimize clinical outcomes this therapy 
should be combined with a treatment which increases T cell infiltration to tumours. For example, 
targeting tumours with tumour necrosis factor superfamily member 14 (TNFSF14) activates 
lymphotoxin β-receptor signalling causing a production of chemokines which recruit significant 
amounts of T cells, creating a T-cell-inflamed microenvironment in previously non-T cell-inflamed 
tumour tissues (Tang et al., 2017). This method of targeting tumours increases their responses to 
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checkpoint blockades and could significantly improve clinical outcomes of anti-PD1/PD-L1 therapy in 
pancreatic cancer. 
However, the nature of pancreatic cancer makes drug delivery rather difficult. In contrast to many 
tumours that are dependent on neo-angiogenesis, pancreatic cancer is poorly vascularised in 
comparison to normal tissue (Olive et al, 2009). The lack of adequate vasculature causes poor perfusion 
and limits the delivery of therapeutic agents from the blood vessel into the TME. Since mAbs are 
administered intra-venously this poor vascularization in pancreatic cancer provides a major challenge 
for drug tumour entry. On top of this, mAbs have inherently poor tissue and tumour penetrance – in 
murine xenograft models, mAbs directed against tumour-specific antigens largely remained in the 
blood with only up to 20% of the administered dose reaching the tumour (Beckman et al., 2007). In 
pancreatic cancer the dense stromal barrier further restricts the ability of mAbs to enter the tumour 
site. Aside from these points, mAbs have other problems associated with their use. Due to their large 
size, antibodies diffuse poorly making them much less effective in the treatment of large tumours (Chen 
et al., 2019). The ‘binding site barrier effect’ is another limitation of mAbs, where high-affinity 
antibodies bind tightly to the first antigen they encounter - that is at the periphery of the tumour 
(Chames et al., 2009). They will not penetrate deeper within the tumour until the antigens on the 
periphery are saturated. Further limitation are the Fc effects of antibodies which lead to depletion of 
effector T cells.  
Instead of a blocking antibody a soluble PD1 extracellular domain could be utilised as a competitive 
inhibitor, counteracting some of the limitation of mAbs. This molecule would be much smaller in size 
and would likely be much more effective in penetrating into the tumour site. The wild-type PD1 
ectodomain does not have a strong binding affinity for PD-L1 and so may not be the best candidate 
for competitive inhibition in a therapeutic setting.  
1.8. Increasing binding affinity of proteins 
Protein binding affinity describes the strength of the binding interaction between a single biomolecule 
and its ligand. In a basic reversible bimolecular binding reaction, molecule A binds to molecule B -
forming a complex. The strength of the interaction between two molecules is measured by the rate of 
the dissociation of the complex – the dissociation constant (KD) (Pollard, 2010). The smaller the KD 
value the greater the binding affinity between the ligand and its target. Binding affinity is influenced by 
non-covalent intermolecular forces such as hydrophobic and Van der Waals forces between the 
molecules, and the presence of other molecules. In this study we seek to enhance the affinity of the 
PD1 protein and generate mutants with increased binding characteristics to PD-L1 in order to 
antagonize the PD1/PD-L1. 
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Traditionally, design of high-affinity proteins was done experimentally, in a time-consuming and costly 
process. The newly developed computational methods have greatly reduced the time and cost of novel 
drug development. The most widely used computational method in drug design is docking and scoring 
which is an efficient method, however it is not the most accurate. It can predict binding modes of 
proteins and can discriminate between ones that will bind and ones that do not, however it cannot 
discriminate between drugs that differ by less than one order of magnitude in affinity (Genheden and 
Ryde, 2015). The alchemical perturbation method is another type of molecular modelling which is 
derived from statistical mechanics and is very accurate. However, it requires extensive sampling of the 
complex, the free ligand in solution as well as of the intermediate states. This makes the process quite 
computationally extensive (Genheden and Ryde, 2015). In between these modelling types lies a method 
of intermediate performance which samples just the complex and the free receptor and ligand 
molecules. The molecular modelling method to develop the high-affinity PD1 variants is of this 
intermediate sub-type, called Molecular Mechanics/Poisson Boltzmann Surface Area (MM/PBSA). In 
this method the free energy of the binding of ligand to receptor is estimated considering the bonded, 
electrostatic, van der Waals interactions and polar and non-polar contributions.  
The MM/PBSA method was used to design PD1 variant proteins in an attempt to increase binding 
affinity. The variants were designed previously in collaboration with Professor Chris Reynolds and Dr 
Kevin Smith as part of a Pancreatic Cancer Research UK pilot project and analysed in the present study.  
1.9. Mesenchymal stem cells as drug delivery vectors 
The high-affinity sPD1 protein alone will not be able to penetrate the pancreatic stroma and reach the 
tumour site; it will require a delivery vector to do so. Mesenchymal stem cells (MSCs) have emerged as 
promising delivery vectors for the delivery of antitumor agents due to their incredible tendency to 
migrate towards sites of inflammation – such as tumours. These migratory properties have the potential 
to serve as drug-delivery vectors to deliver effective, targeted therapy to tumours (Gao et al., 2007). 
MSCs are heterogenous group of progenitor cells and play important roles in tissue regeneration. They 
are characterised by the expression (CD73, CD90, CD105) and lack of (CD34, CD45, CD19 CD11b, HLA-
DR) haemopoietic cell markers on their surface. Additionally, they adhere to plastic in culture and have 
the ability to differentiate into osteoblasts, adipocytes and chondroblasts in vitro (Rojewski et al., 2008). 
It has been shown that MSCs are actively attracted to hepatic carcinoma, breast cancer and pre-
metastatic niches (Xie et al., 2017; Ma et al., 2015; Arvelo et al., 2016). This tumour tropism is part of 
the normal tissue repair mechanism where MSCs are recruited to sites of tissue injury and 
inflammation. Tumour migration is thought to occur via a chemo-gradient where MSCs travel towards 
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inflammatory signals (Son et al, 2006) and the migration is regulated by various cytokines (such as VEGF, 
PDGF, HGF, HMGB1) (Eliopoulos et al., 2008).  
Due to these features, MSCs have been genetically modified in many studies to express peptides and 
protein with anti-tumour properties. The first such application of MSCs in targeted cancer therapy was 
a delivery of IFN-β which successfully inhibited the growth of malignant cells (Studeny et al., 2002). The 
study found that the tumour microenvironment preferentially promotes engraftment of MSCs 
compared to other tissues and the MSCs successfully produced biological agents in mouse tumour 
models. Significant anti-cancer effects against tumours of brain, ovary, liver kidney and pancreas were 
observed with MSCs genetically engineered to express suicidal genes (thymidine kinase, cytosine 
deaminase, carboxylesterase) (Song et al., 2011; Yin et al., 2011). Several anticancer therapies using 
MSCs are in various stages of clinical development such as MSCs modified to express TNF-related 
apoptosis -inducing ligand (TRAIL) and induce cell death of tumours (Cheng et al., 2019). These studies 
show supporting evidence that the use of MSCs to deliver therapeutics to pancreatic cancer will be 
effective. 
 
1.10. Aims and hypotheses 
The computationally-designed PD1 variants will be designed as soluble proteins (sPD1) and their 
binding properties to PD-L1 analysed. The variant with the strongest binding affinity will be selected 
and engineered into mesenchymal stem cells (MSCs) for expression. The hypothesis is that the MSCs 
containing the sPD1 – termed MSC.sPD1 – will travel to the inflamed pancreas via a chemokine gradient. 
The MSC.sPD1 will then secrete sPD1 into the TME. sPD1 will strongly bind to PD-L1 on cancer cells, T 
cells as well as the surrounding cells in the TME and will outcompete the binding of PD1 on T cells. This 
will block the PD1/PD-L1 -mediated inhibition of TCR signalling and will allow cytotoxic T cells to respond 
to neoantigens once more (Figure 1.10.1). Additionally, it may disrupt PD1 signalling on Tregs and 
inhibit their immunosuppressive functions. Altogether these effects will allow the immune system cells 




Figure 1.10.1. Interruption of PD1/PD-L1 signalling with mesenchymal stem cells which secrete soluble PD1 
(sPD1.MSC). When pancreatic cancer cells begin expressing PD-L1 on their surface it interacts with PD1 on T cells 
and inhibits T cell and CD28 co-receptor signalling and prevents the activation of transcription factors which would 
go on to activate genes regulating proliferation and T cell effector functions. This is a method of cancer immune 
evasion and allows pancreatic cancer to escape immune-mediated death. Introduction of sPD1.MSC would bind 
to PD-L1 on the cancer and prevent it from interacting with the PD1 on T cells. This would reactivate TCR and 
















2.1. Generation of the pcDNA.sPD1WT 
The sPD1WT fragment was synthesised by an external manufacturer (DC Bioscience, Dundee). It was 
then amplified with a PCR reaction. The sPD1WT fragment was cloned into the pGEM T-Easy vector, 
which was obtained from Promega Systems (Catalog no #A1360) with T4 ligase to generate a 
pGEM.sPD1WT construct. The ligation reaction was transfected into competent Top10 E. Coli cells and 
grown in LB agar supplemented with Ampicillin, X-Gal and IPTG to allow selection of positive bacterial 
clones. A positive colony was picked and further cultured in LB media. The pGEM.sPD1WT plasmid 
construct was then isolated with the miniprep technique. pGEM.sPD1WT was digested with EcoRI and 
NotI restriction enzymes and cloned into the pcDNA3 plasmid vector which was obtained from 
ThermoFisher Scientific (Catalog no #V790200). This resulted in a final pcDNA.sPD1WT construct. 
2.2. – Generation of variants with higher binding affinities 
To generate the MM/PBSA variants, site directed mutagenesis on pcDNA.sPD1WT was conducted. A PCR 
reaction was performed using primers which contained the desired mutations to generate sPD11, 
sPD127 and fragments with introduced point mutations. The cloning procedure described in section 2.1 
was then performed to produce the pcDNA.sPD11 and pcDNA.sPD127 and constructs.  
2.3. Generation of the sPD1.pFUSE constructs 
The pFUSE-hIgG1-Fc vector was obtained from InvivoGen (Catalog no #pfuse-hg1fc1).  
The sPD1 fragment was amplified from the pcDNA.sPD1 expression constructs by using primers with 
EcoRI and BglII restriction sites. The sPD1 DNA fragment was separated from the pcDNA3 vector via gel 
electrophoresis, purified and isolated using the miniprep procedure. The sPD1 fragment was then 
cloned into pFUSE-hIgG1-Fc at the EcoRI and BglII restriction sites with T4 ligase. The ligation reaction 








2.4. Agarose Gel Electrophoresis parameters 
The QuickLoad® Purple 1Kb Plus DNA Ladder was purchased from New England BioLabs (Catalog no 
#N0550S). 
DNA was mixed with Sybrgreen and Loading Buffer. Components of different sample types are shown 
below (Table 2.4.1). Samples were tested on 1% agarose gel in 1X TAE buffer [100 V, 40 mins]. All 
samples were loaded on gel with a DNA Ladder.  
Table 2.4.1. Components of samples used during gel electrophoresis with the volumes shown. 
Sample type DNA Sybrgreen Loading Buffer 
PCR sample Whole PCR sample 5 µl 5 µl 
DNA for Analytical Digest 10 µl 5 µl 5 µl 
DNA for Extraction Digest 20 µl 5 µl 5 µl 
DNA Ladder 1 µl 5 µl 5 µl 
 
2.5. DNA gel extraction 
DNA was purified from the gel using Sigma-Aldrich GenElute Gel Extraction Kit (Catalog no #NA111) 
following the manufacturer’s instructions. The DNA concentration was tested with a Nanodrop reader.  
2.6. Plasmid Miniprep 
Minipreps were done using the GenElute Sigma-Aldrich Plasmid Miniprep Kit (Catalog no #PLN10), 
following the manufacturers guidelines. 1.5 mL of overnight cell cultures was used. The concentration 
of eluted DNA was measured using a nanodrop.   
2.7. DNA Plasmid Midiprep 
The Midiprep procedure was done using the NucleoBond® Xtra Midi Kit. For details on E. Coli cell culture 
guidelines, refer to section 2.8. 
A 100 mL of overnight E. Coli cell culture was centrifuged [4,500 g, 10 mins]. The pellet was resuspended 
in 8 mL Resuspension Buffer and treated with Lysis Buffer [5 mins] and neutralized with Neutralization 
Buffer [8 mL]. The NucleoBond® Xtra Column was treated with Equilibration Buffer [12 mL] and loaded 
with the cell lysate. Equilibration Buffer [5 mL] was used to wash the column and the filter was 
discarded. The column was then washed with Wash Buffer [8 mL]. Room temperature isopropanol [3.5 
mL] was added into a fresh collection tube into which the plasmid DNA was eluted into using Elution 
Buffer [5 mL]. The DNA plasmid elute was concentrated with a NucleoBond Finalizer. The plunger was 
26 
 
removed from a 30 mL syringe and a NucleoBond finalizer was attached to the outlet. The previously 
collected elute was then added to the syringe and the plunger was reinserted, and the mixture was 
slowly pressed through the NucleoBond Finalizer and the flow-through discarded. 70% ethanol [2 mL] 
was slowly pressed through the NucleoBond Finalizer and the flow-through was discarded. The 
NucleoBond Finalizer was dried until no ethanol was present. The NucleoBond Finalizer was then 
attached to a 1 mL syringe outlet and Redissolving Buffer TRIS [400 µl of] was added to the syringe and 
the plasmid DNA was slowly eluted into a collection tube.  
2.8. E. Coli culture conditions  
The transformation reaction is mixed with 300 µl of LB medium and cultured for 1 hour at 37°C. The 
cells were then grown on LB agar plates overnight [37°C]. For sPD1.pGEM selection and expansion, the 
agar was supplemented with 100 µg/mL Ampicillin, 40 µg/mL of X-Gal and 1 mM IPTG. For sPD1.pcDNA 
construct expansion the agar was supplemented with 100 µg/mL Ampicillin only. To expand 
sPD1.pFUSE constructs, LB agar was supplanted with 250 µg / mL Zeocin. 
For miniprep isolation (Section 2.6) of recombinant plastic vectors, a positive colony was grown in 5 mL 
of LB supplemented with 100 µg /mL Ampicillin or 250 µg / mL Zeocin for pcDNA3 and pFUSE T-Easy 
vectors respectively and cultured overnight [37°C, 300 rpm].  
For midiprep isolation (section 2.7) of recombinant plasmid vectors, a single transformed colony was 
picked from a freshly streaked agar plate and placed in 3 mL of LB medium supplemented with 100 
µg/mL Ampicillin or 250 µg / mL Zeocin for the pcDNA3 and pFUSE respectively, and grown while shaken 
[8 hours, 37°C, 300 rpm]. 100 µl of this culture was placed in 100 mL of LB medium supplemented with 
the antibiotic of choice and grown overnight [37°C, 300 rpm]. 
2.9. CHO cell Culture 
All cell culture was undertaken in a microbiological safety cabinet using aseptic techniques to ensure 
sterility. Chinese Hamster Ovary (CHO) cells were maintained in DMEM media, supplemented with 10% 
Foetal Bovine Serum (FBS).  
2.10. CHO cell transfection 
CHO cells cultured at 70% density were transfected. A mixture of 3 µg pcDNA.sPD1 DNA, FuGene at a 
3:1 ratio of FuGene to DNA and 100 µl serum-free media was added to each well of a 6-well plate. The 
mixture was added in a drop-wise manner at various spots in each well. The cells were incubated for 2 





ELISA tests were carried out using a standard R&D system® Elisa Kit according to the manufacturer’s 
instructions. The antibodies used were also obtained from R&D Systems – Human PD-1 Antibody 
(Catalog no #AF1086) for the capture antibody, Human PD-1 biotinylated antibody (Catalog no 
#BAF1086) for the detection antibody and Recombinant Human PD-1 Fc Chimera Protein (Catalog no 
#1086-PD) for the standard PD-1 sample. The PD-1 capture and detection antibodies were both used 
at the concentration of 5.6 µl/mL, diluted in blocking buffer (1% BSA in PBS). The wash buffer used was 
0.05% Tween in PBS. Sample absorbance was read at 450 nm in a BMG Labtech Clariostar 
fluorophotometer. 
2.12. Solid-phase protein competition assay 
The biotin-labelled PD1 Fc-fusion protein was obtained from BPS bioscience (Catalog no #1109). 
Recombinant human PD-L1 Fc-chimera protein was obtained from R&D systems (Catalog no #156-B7-
100). Streptavidin-HRP and the Colour Development solution was obtained from R&D system® Elisa Kit. 
The Wash Buffer used is 0.05% Tween in PBS. The Blocking Buffer is 1% BSA in PBS.  
Wells in a 96-micro well plate were coated with 50 µl of PD-L1 at a concentration of 2 µg/µl. The 
microplate was incubated at overnight [4°C].  PD-L1 was aspirated and Wash Buffer [100 µl] was added 
to the wells and removed; this step was repeated three times. The plate was patted against a paper 
towel until dry. Wells were then treated with blocking buffer [100 µl] and incubated at room 
temperature [1 hour]. The test samples consisted of CHO supernatant with 50 or 20 ng of the sPD1 
variant of interest and an equivalent amount biotin-labelled PD1 (unless stated otherwise) and adjusted 
with PBS to make a final sample volume of 50 µl. Samples were incubated at room temperature [2 
hours].  The wash procedure was repeated, and the wells were blocked with Blocking Buffer [100 µL] 
and incubated [10 mins] and washed again. 100 µl of streptavidin-HRP was added at the working 
concentration and incubated at room temperature [20 min], while shielded from direct light. The wash 
procedure was repeated, and wells were treated with Blocking Buffer [100 µl]. Next, tetramethyl-
benzidine was added - the colorogenic substrate, and incubated at room temperature for 3 minutes. 
The reaction was stopped with 50 µl 1M Phosphoric acid. The absorbance was recorded at 450 nm 






2.13. Unspecific Binding Testing 
Recombinant human PD-L1 (Catalog no #9049-B7-100) and PDL-2 (Catalog no #9075-PL-100) His-tag 
proteins were obtained from R&D Systems. Human PD-1 biotinylated antibody (Catalog no #BAF1086) 
was also obtained from R&D Systems. The Wash Buffer used is 0.05% Tween in PBS. The Blocking Buffer 
is 1% BSA in PBS. 
Wells in a 96-well microplate were coated with coated with 100 µl of His-PD-L1, His-PD-L2 and His-GST 
suspended in PBS at a concentration of 2 µg/µl. The microplate was incubated overnight [4°C]. The 
wells were then aspirated and washed three times with Wash Buffer [400 µl], dried by blotting against 
a paper towel. Wells were then blocked with Blocking buffer [400 µl] at room temperature [1 hour]. 
Test samples consisted of CHO supernatant containing 20 and 50 ng of sPD1 diluted in PBS with a total 
sample volume of 100 µl. The samples were added to appropriate wells alongside a negative control 
sample without sPD1-containing supernatant present.  Samples were incubated at room temperature 
[2 hours]. The washing procedure was repeated. Wells were then incubated with the anti-PD1, 
biotinylated antibody which was diluted with PBS to the working at the concentration of 5.6 µL/mL. The 
wells were aspirated and washed and coated with streptavidin-HRP [100 µl] at a 1:40 dilution ratio., 
and incubated at room temperature [20 mins], while shielded from light. The wash procedure was 
repeated, and wells were treated with the Colour Development solution [100 µl] and incubated at room 
temperature [20 mins]. The reaction was stopped with 100 µl of the stop solution (1M HCL) and the 
sample absorbance was read at 450 nm in a Clariostar microplate reader. 
2.14. Surface staining and FACS analysis 
The human PD-L1 PE-conjugated antibody (Catalog no #FAB1561P) and the mouse IgG1 PE-conjugate 
antibody (Catalog no #IC002P) were both purchased from RnD Systems. Biotin -labelled PD1, obtained 
from BPS Bioscience (Catalog no #711090). The streptavidin-PE conjugate was obtained from 
ThermoFisher Scientific (Catalog no #12-4317-87). 
PancTuI cells were treated with IFN-γ to induce surface PD-L1 expression. The growth medium was 
transferred into a universal tube and the cells were washed with 2.5 mL of PBS. 2 mL of Trypsin was 
added, and the cells were incubated until they detached from the membrane and transferred into the 
universal tube containing the growth medium. The cell suspension was adjusted to a concentration of 
2x106 cells/mL in ice cold PBS. A haemocytometer was used to count the cells and 2x106 cells were used 
for the assay. Each cell sample was centrifuged [5000 xg, 1 minute] and the supernatant was discarded.  
PancTuI cells were treated with the PD-L1 PE-conjugated antibody. To test for background staining a 
mouse IgG1 PE-conjugate antibody was used. PancTuI were treated with 1 µl of the appropriate 
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antibody and incubated for 20 mins [4°C]. The cells were then washed with 1 mL PBS, centrifuged [5000 
xg, 1 min] and the supernatant was discarded Next, 50 µl of PBS was added to the cells and gently mixed 
and the signal was measured using BD Acuri C6 flow cytometer. 
To test sPD1 variant competition, CHO supernatant containing 50 ng of sPD1 protein was added to the 
sample with 50 ng of Biotin -labelled PD1 and incubated [4°C, 20 min]. The sample volume was adjusted 
to 50 µl with PBS. Each sample was then washed with 1 mL of PBS, centrifuged [5000 xg, 1 min] and the 
supernatant was discarded. 1 µl of Streptavidin-PE conjugate was added to the samples, adjusted with 
PBS to make a 50 µl total reaction volume and incubated [4°C, 20 min]. The washing, centrifugation and 
supernatant removal steps were repeated and then 50 µl of PBS was added to the cells and gently 
mixed and the signal was measured using BD Acuri C6 flow cytometer. 
2.15. Adenoviral vector generation for sPD1 expression 
To generate an adenoviral expression vector for sPD1, the pAd/CMV/V5-DEST vector was used, 
obtained from Invitrogen (Catalog no #V493-20).  
First, an LR recombinant reaction between pFUSE.sPD1HAC and the pAd/CMV/V5-DEST vector was set 
up. The components of each reaction (Table 2.15.1) were added to a 0.5 ml microcentrifuge at room 
temperature and mixed. To include a negative control, a separate reaction was set up which will not 
contain LR Clonase II enzyme mix.  
Table 2.15.1. Sample components of the LR recombinant reaction between pFUSE.sPD1HAC and pAd/CMV/V5-DEST vector  
Component Sample  Positive Control 
pFUSE.sPD1HAC (50-150 ng / 
reaction)  
1-7 µl -  
PETR-gus (50 ng/ µl) - 2 µl 
pAd/CMV/V5-DEST vector 2 µl 2 µl 
TE Buffer, pH 8.0 To 8 µl 4 µl 
 
Next, 2 µl of the LR Clonase®II enzyme mix was added to each sample excluding the negative control, 
mixed well and incubated at 25°C overnight. 1 µl of Proteinase K solution was added to each reaction 
and incubated for 10 mins at 37°C. Next, competent Top10 E. Coli cells were transformed with 3 µl of 
the LR recombination reaction. Positive clones were cultured with ampicillin. The recombinant vector 
was isolated and purified using the miniprep procedure (section 2.6). 
The adenovirus-containing cells and media were harvested into a sterile tube and the adenoviral stock 
was amplified following Life Technologies’ ViralPower Adenoviral Expression System guidelines. 
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2.16. Mesenchymal stem cell transduction 
The MSCs used in this study were bone-marrow derived. They were cultured in complete StemMACSTM 
culture media from Miltenyi Biotec (Catalog no #130-104-182). On the day of the transduction the cell 
culture medium was removed from the cells and a MOI of 500 of freshly thawed adenoviral stock was 
added to each well. The plate was incubated overnight [at 37°C]. The following day the virus-containing 
medium was removed and replaced with fresh, complete culture medium. The cells were then grown 



























3.1. Designing a soluble PD1 DNA construct 
In order to generate a soluble version of the PD1 protein, the wild-type PD1 protein sequence was 
retrieved first. The PD1 sequence was modified to exclude the cytoplasmic and transmembrane 
domains. The location of the extracellular domain of PD1 is 109 nt – 558 nt; a visual representation of 
the linear structure of PD1 and the extracellular domain position is shown in Figure 3.1.1. To enable 
sPD1 protein secretion an exogenous signal peptide was added to the N-terminus of the protein – this 
sequence directs the protein to the endoplasmic reticulum and tags it for eventual extracellular 
secretion. The signal peptide was derived from the human fibrillin gene. A Furin protease cleavage site 
was also introduced to facilitate the removal of the localisation peptide thus producing a mature wild-
type sPD1 protein – termed sPD1WT. This method of generating soluble protein variants has achieved 




Figure 3.1.1. Design of a soluble wild-type PD1 (sPD1WT) protein variant where the extracellular domain is isolated 
and fused with a localization sequence and a Furin cleavage site. A. A linear diagram indicating the key domains 
of PD1. It consists of a 450 bp extracellular domain (yellow), a transmembrane region (blue) and an intracellular 
domain (red). The C terminus and N terminus are indicated. B. A diagram showing the design and sequence of 
soluble PD1WT. The extracellular domain is isolated from the full PD1 sequence and fused with a localisation 
sequence (green) and a Furin cleavage site (orange). C. The final sPD1WT peptide product with the localisation 
peptide and Furin cleavage site shown.  
 
To produce the sPD1WT expression construct the sPD1WT DNA fragment was amplified using primers 
with introduced NotI and EcoRI restriction sites (Figure 3.1.2). The forward and reverse primers contain 
Kozak and Stop Codon sequences respectively which will facilitate the beginning and end of replication 
of sPD1 within cells. During PCR, DNA Polymerase adds a single deoxyadenosine base to the 3’- ends of 
the amplified fragments. The pGEM-T Easy vector contains complimentary 3’ terminal thymidine 




Figure 3.1.2. PCR amplification of sPD1WT with the primer binding location and final PCR product shown. A. The 
primer pair sequence is shown here with EcoRI (green), NotI (purple) restriction enzyme sites highlighted. The 
forward primer contains a Kozak consensus sequence (grey) to initiate DNA translation and the reverse primer 
contains a Stop sequence (blue) to terminate DNA translation. The red sequence in both primers represents the 
sequence complimentary to sPD1. B.  The primer annealing location is shown here. The sPD1 DNA strands are 
visualised in blue. C. The final sPD1 DNA fragment generated from the PCR process. The 3’ adenosine overhangs 
(black) are a feature of DNA polymerase which adds these during DNA replication. The EcoRI and NotI digestion 
sites are indicated with a red line.  
 
The pGEM-T-Easy vector contains an ampicillin resistance gene and a LacZ operon to allow for selection 
of positive bacterial clones (Figure 3.1.3). The PCR sPD1WT fragment and pGEM-T-Easy vector were 
ligated to generate the pGEM.sPD1WT construct. Insertion of the sPD1WT fragment into the pGEM-T-
Easy plasmid disrupts the LacZα gene within the Lac operon which normally leads to X-gal hydrolysis 
and a subsequent colour change of the resulting bacterial clones after transformation with the plasmid, 
from blue for the simply ligated pGEM-T-Easy plasmid to white for insert-containing/positive plasmids. 
White colonies were amplified in small liquid cultures and the resulting plasmid DNAs after Miniprep 
purification analysed by restriction digests for the presence of the pGEM.sPD1WT construct. One positive 





Figure 3.1.3. A visualisation of the genetic engineering procedure to generate an sPD1WT expression construct 
using pGEM T-Easy as the intermediate cloning vector and pcDNA3 as the final expression vector. The pGEM T-
easy vector contains thymidine overhangs and is a compatible vector for PCR sPD1WT variant products which have 
adenosine base overhangs due to the nature of DNA Polymerase replication. The DNA undergoes a ligation 
reaction to generate a pGEM.sPD1WT construct. pGEM.sPD1WT is cleaved with NotI and EcoRI enzymes to release 
the sPD1WT fragment from the pGEM vector. A pcDNA3 vector is cleaved with NotI and EcoRI enzymes to produce 
complimentary overhangs to the sPD1 fragment and the two are ligated to generate the final pcDNA.sPD1WT 
vector. 
 
The sPD1WT fragment was then released from the pGEM vector backbone via restriction with EcoRI and 
NotI at the introduced enzyme cleavage sites (Figure 3.1.2). Next, it was inserted into a pcDNA3 plasmid 
vector – a mammalian expression vector containing the human cytomegalovirus immediate-early 
(CMV) promoter and, among others, NotI and EcoRI cleavage sites in the multi-cloning site where DNA 
fragments are usually inserted. Ligation between sPD1WT and pcDNA3 resulted in a final expression 
construct termed pcDNA.sPD1WT. A full plasmid map of pcDNA.sPD1WT is shown below (Figure 3.1.4). 





Figure 3.1.4. A map of the recombinant pcDNA.sPD1WT expression construct with the key features shown. The 
pcDNA.sPD1WT construct is 5945 bp in size. It contains an ampicillin resistance gene (green) for selection of 
positive bacterial clones, a CMV promoter and enhancer (yellow) which are required for transient expression of 
transgenes, and other essential plasmid elements including origin of replication (Ori). The sPD1WT fragment was 
cloned into the multidrug insertion site with EcoRI and NotI enzymes at the location 952-1524 bp (red). 
 
3.2. sPD1WT protein production 
To generate the sPD1WT protein Chinese Hamster Ovary (CHO) cells were transfected with 
pcDNA.sPD1WT. The cell supernatants were analysed for sPD1WT protein presence by ELISA.  The results 
confirm successful extracellular sPD1WT protein secretion (Figure 3.2.1). The average sPD1WT 
concentration was 1380 ng / mL. A control sample consisting of supernatants from CHO cells 
transfected with a non-recombinant pcDNA3 vector tested negative for sPD1 protein presence. These 
results confirm successful sPD1WT production from the pcDNA.sPD1WT expression construct. The 





Figure 3.2.1. sPD1WT protein concentration in the supernatant of CHO cells transfected with the pcDNA.sPD1WT 
construct. Protein concentration in the supernatant was determined via ELISA. The control sample is a 
supernatant sample from CHO cells transfected with a non-recombinant pcDNA3 parental plasmid. Data is 
expressed as mean ± SE and are representative of four independent experiments.  
 
3.3. Testing sPD1WT binding to PD-L1 in a cellular competition assay 
To ensure sPD1WT can bind to its ligand - PD-L1, a competition binding experiment was conducted. 
Pancreatic cancer tumour cells (PancTuI) were stimulated with IFN-γ to induce expression of PD-L1 on 
their surface, to better reflect the nature of cancer cells in vivo where PD-L1 is upregulated. PD-L1 was 
detected with an anti-PD-L1 antibody (Figure 3.3.1). A sample of IFN-γ-stimulated PancTuI cells was 
compared to a sample of non- IFN-γ-stimulated PancTuI cells. Background staining was detected using 
an isotype control. The results show that PancTuI cells stimulated with IFN-γ express more PD-L1 than 
the non-stimulated PancTuI cells, visualised by a peak shift to the right. This confirms successful PD-L1 
induction on the surface of PancTuI cells. The PD-L1 -positive PancTuI cells will be used in the protein 




Figure 3.3.1. Induction of PD-L1 on the PancTuI cell surface via IFN-γ stimulation. 2x106 PancTuI cells either 
stimulated (yellow) or non-stimulated (red) with IFN-γ were incubated with a PE conjugated anti-PD-L1 antibody. 
Background staining of the IFN-γ-stimulated PancTuI cells was detected with an isotype control – PE mouse IgG1 
(grey). 
 
IFN-stimulated PancTuI cells which tested positive for PD-L1 expression were then incubated with CHO 
supernatants containing 50 ng of sPD1WT and 50 ng of a commercial recombinant PD1 protein (rPD1), 
engineered with a biotin tag. The assay was performed with a negative control to detect the background 
radiation and a control sample (IFN-γ stimulated PancTuI cells incubated with supernatant from CHO 
cells that were transfected with a non-recombinant pcDNA3 plasmid vector). The results (Figure 3.3.2) 
show a decrease in fPD1 binding when sPD1WT is present in the sample (visualised by a peak shift to the 
left). This signifies sPD1WT successfully binds to PD-L1 on the PancTuI surface and is competing with 






Figure 3.3.2 Flow cytometry results showing competitive binding of recombinant PD1 (rPD1) and sPD1WT to PD-
L1 on the surface of PancTuI cells. PancTuI cells were stimulated with IFN-γ to induce PD-L1 expression on their 
surface. The binding affinity of sPD1WT to PD-L1 was then analysed in a competition assay where sPD1WT competes 
for the binding site of PD-L1 on the surface of PancTuI cells with rPD1– a commercial recombinant PD1 protein 
engineered with a biotin tag. First the full binding capacity of rPD1 was tested (blue) – 2x106 PancTuI cells were 
coated with 50 ng of rPD1 and the bound rPD1 was detected with streptavidin-PE conjugate and the signal 
intensity was measured via flow cytometry. To detect protein competition (red), 2x106 PancTuI cells were 
incubated with 50 ng of sPD1WT and 50 ng of rPD1. Unbound protein was washed away and PancTuI cells were 
incubated with a streptavidin-PE conjugate and the signal intensity was measured. A negative control to detect 
background radiation (grey) was tested by incubating 2x106 PancTuI cells with the streptavidin-PE conjugate.  
 
3.4. Establishing parameters of the microplate-based sPD1 Competition Assay  
The cellular protein competition assay can be time-consuming and expensive due to the cell culture 
and maintenance. To make sPD1 variant testing more efficient a solid-phase competition assay was 
developed. The assay is derived from the enzyme-linked immunosorbent assay (ELISA) methodology 
(Figure 3.4.1). It consists of three main stages; immobilisation of commercial, recombinant PD-L1 
protein- to the wells of the assay plate, the incubation stage with sPD1 proteins for protein-protein 
interaction to establish, and the detection of bound sPD1. In the protein interaction stage, the plate is 
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coated with the sPD1 variant of interest and a commercial, recombinant PD1 protein (rPD1) with an 
added biotin tag. In the protein-protein interaction stage sPD1 and rPD1 compete for the PD-L1 binding 
site. The bound rPD1 is quantified via an enzyme-linked reaction which results in a measurable colour 
change in the assay. The intensity of the colour change is quantitively dependant on the of rPD1 bound 
to PD-L1. Comparison of signal intensities between the test sample with the sPD1 protein variant and 
rPD1 and the control sample with just rPD1, allows for analysis of the binding of sPD1 to PD-L1. 
 
 
Figure 3.4.1. Principle behind the solid-phase protein competition assay to analyse the binding of sPD1 to PD-L1. 
A) Recombinant PD1 (rPD1) engineered with a biotin tag and unlabelled sPD1 protein variant are incubated 
together on a microplate with PD-L1 attached to the surface. After an incubation period the unbound protein is 
removed by washing. B) The plate is coated with a streptavidin-HRP conjugate protein which strongly binds to 
biotin in a non-covalent manner. The unbound conjugate protein is washed away. C) The addition of TMB 
substrate results in a colour change catalysed by the HRP enzyme in the wells, which can be measured. sPD1 
protein variants can be tested for their ability to outcompete the binding of rPD1 using this assay. A weak signal 
suggests that sPD1 is successfully outcompeting rPD1 binding and therefore has a higher affinity for PD-L1. 
To provide a sensitive assay for effective testing of sPD1 variants, the assay parameters were tested 
and optimised. To determine the working concentration of rPD1 for the assay a PD-L1 saturation curve 
was generated. rPD1 dilutions in the concentration range of 10 - 900 ng were added to wells with 100 
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ng of PD-L1 immobilised to the surface and allowed to reach binding equilibrium. The signal intensity 
of each well was recorded via spectroscopy and the optical density value was converted into a 
percentage of PD-L1 saturation and plotted (Figure 3.4.2). For a sensitive assay, the protein association 
must be higher than the dissociation rate, which occurs in the linear range of the curve. In this assay, 
this is between 10 and 100 ng with the curve starting to flatten at 200 ng - and binding beginning to 
reach equilibrium at 500 ng of rPD1. Thus, it was decided to use rPD1 concentrations between 10 and 





Figure 3.4.2 Saturation of PD-L1 with recombinant PD1 (rPD1). A microplate with PD-L1 attached to the surface 
was incubated with a rPD1 (PD1 engineered with a biotin tag) in concentration ranges of 10 – 900 ng to generate 
a PD-L1 saturation curve. Data shows percentage of PD-L1 saturation at different rPD1 concentrations. 
 
To determine the appropriate concentration of PD-L1 for the assay to be sensitive, an experiment was 
conducted where PD-L1 was the variable parameter. The microplate surface was coated with PD-L1 
concentrations of 0, 12.5, 25, 50 and 100 ng. The wells were incubated with either 20 or 50 ng of rPD1. 
The optical density data was converted into a percentage value where the standard 100% rPD1 binding 
sample is the 100 ng of PD-L1 incubated with 50 ng of rPD1 sample. The assay results are shown in 
Figure 3.4.3. Coating the plate with 0 ng of PD-L1 did not result in a signal from rPD1 indicating that it 
does not bind to the plate surface or the BSA protein. Increasing the coating surface of PD-L1 leads to 

























signal with no significant variation between the 20 ng and 50 ng rPD1 concentration groups, suggesting 
an excess of rPD1 protein in both samples. Increasing the PD-L1 coating concentration to 25 ng results 
in a higher overall signal, however no distinct difference between the different rPD1 concentration 
conditions was observed. An increase to 50 ng of PD-L1 resulted in 54% more rPD1 binding in the 50 ng 
rPD1 group compared to the 20 ng group. Coating with 100 ng PD-L1 resulted in the highest signal 
intensity and the highest sensitivity to distinguish between the different rPD1 concentration groups. An 
88% signal increase has been recorded between the 20 ng and 50 ng rPD1 concentration samples in 
this group. In future experiments, each well will be coated with 100 ng of PD-L1 as this condition 
provides for the highest assay sensitivity. 
 
Figure 3.4.3. Percentage of recombinant PD1 (rPD1) Binding PD-L1 coating concentration in a solid-phase 
microplate-based assay. Microplate wells were coated with PD-L1 (0, 12.5, 25, 50, 100 ng). The wells were 
incubated with either 20 or 50 ng of rPD1 and the signal intensity was measured and converted into % of rPD1 
binding. Data is expressed as mean ± SE of duplicate wells. 
 
 
3.5 Generation of sPD1 variants with mutations to increase binding affinity to PD-L1 
The sPD1 variants were designed using the MM/PBSA method; single point mutations were introduced 
into the protein coding sequence to increase the sPD1 binding affinity to PD-L1. These mutations were 
introduced via site-directed mutagenesis of the sPD1WT fragment using primers containing desired 
mutations. Variants termed sPD11 and sPD127 were generated in this way and were transfected into 
CHO cells alongside sPD1WT. The supernatants were analysed to determine protein concentrations via 























mL. The expression level of sPD127 was on average 1017 ng / mL. Variant sPD11 exhibited an average 
expression level of 1027 ng / mL. Overall, there is no evidence that any of the introduced mutations is 
having an adverse effect on sPD1 protein production and expression.  
 
 
Figure 3.5.1. sPD1 variant protein concentration in the supernatant of transfected CHO cells. CHO cells were 
transfected with pcDNA.sPD1 variants and sPD1 protein concentration in cell supernatants were determined by 
ELISA. Data is expressed as mean ± SE of duplicate wells and are representative of three independent 
experiments.  
 
The sPD1 variants were then tested for the strength of their binding to PD-L1 using the solid-phase 
protein competition assay. CHO supernatant containing 50 ng of sPD1 variant and 50 ng of rPD1 was 
added to wells coated with 100 ng of PD-L1. Variant binding to PD-L1 was compared to that of sPD1WT 
with this setting the 100% rPD1 binding. The results (Figure 3.5.2) show that the variants are moderately 
more effective than sPD1WT at binding to PD-L1 and can outcompete rPD1. On average, sPD127 
outcompetes 22% more rPD1 than sPD1WT. sPD11 outcompetes 26% more rPD1 than sPD1WT and is the 
most effective protein inhibitor out of the tested variants. These are promising results showing that 
































Figure 3.5.2. Solid-phase protein competition assay testing sPD1 variant binding (sPD1WT, sPD127 and sPD11) to 
PD-L1 at different recombinant PD1 (rPD1) concentrations. A microplate with 100 ng of PD-L1 attached to the 
surface of each well was incubated with 50 ng of sPD1WT, sPD127or sPD11 with 50 ng of rPD1. All data is 
expressed as mean ± SE of duplicate wells and are representative of three independent experiments.  
 
Based on the hypothesis that PD1 and PD-L1 interact as dimers rather than monomers, we generated 
a tetramerisation variant of sPD1 (sPD1TETR) through the addition of a p53-derived tetramerisation site 
into the DNA sequence. The theory is that by enforcing a tetramer structure of sPD1, the dimeric 
interaction between sPD1 and PD-L1 will be able to occur more readily and therefore this variant will 
have an increased binding affinity to PD-L1 than the monomeric sPD1. sPD1TETR was expressed in a 
pcDNA.sPD1TETR expression construct and used to transfect CHO cells alongside sPD1WT to observe if 
the introduced tetramerisation site interferes with protein production or secretion. The ELISA results 
(Figure 3.5.3) show that the mean concentration of sPD1TETR in cell supernatant was 1194 ng / mL and 
the mean concentration of sPD1WT was 1177 ng / mL. While the amount of protein expression varied 
between transfection experiments, the sPD1WT and sPD1TETR were expressed in comparable 
concentrations in each of the individual experiments. From these results, it can be concluded that a 




Figure 3.5.3. Average protein concentration of sPD1WT and sPD1TETR in CHO cell supernatant. The supernatants 
of CHO cells transfected with pcDNA.sPD1WT and pcDNA.sPD1TETR expression constructs were analysed by ELISA 
to determine the sPD1 (variant) concentration in cell. Data is expressed as mean ± SE of duplicate wells and are 
representative of three independent experiments.  
 
To determine if the tetramerisation site does, in fact increase the binding of sPD1 to PD-L1, sPD1TETR 
was assessed in a solid-phase binding assay and compared to a control sample with sPD1WT present as 
the rPD1 competitor. The results (Figure 3.5.4) show that the addition of a tetramerisation site leads to 
less rPD1 binding to PD-L1 and the tetramerization site therefore appears to increase the affinity to PD-
L1. The results show that sPD1TETR decreases rPD1 binding by 24% compared to sPD1WT. This finding 
opens up the possibility of a future design of a tetramerisation domain containing high-affinity sPD1 




Figure 3.5.4. Comparison of recombinant PD1 (rPD1) binding to PD-L1 in samples with sPD1WT and sPD1TETR as 
competitors. PD-L1 was immobilised to the microplate surface ( 100 ng per well) and wells treated with 
supernatant from transfected CHO cells that contained either sPD1WT or sPD1TETR protein, together with 50 ng of 
rPD1. Values were converted into percentage wherein the binding of rPD1 in the presence of sPD1WT is set as 
100%. Data is expressed as mean ± SE of duplicate wells and are representative of three independent 
experiments.  
 
3.6 Generation of a soluble High Affinity Consensus (HAC) sequence PD1 variant 
A published high-affinity consensus sequence mutant (HAC) of PD1 was found in the literature (Maute 
et al., 2015). This sequence contains 10 point mutations, as opposed to our variants which only contain 
a single point mutation. It was also generated in a soluble form using our general design with signal 
peptide and Furin cleavage site and termed sPD1HAC (Figure 3.1.3). A pcDNA.sPD1HAC expression 
construct was generated (Section 3.1) and transfected into CHO cells to express the protein. An ELISA 
was used to measure protein expression of this variant. The results revealed that sPD1HAC is expressed 
in much lower concentrations than other variants - the average sPD1HAC concentration was 15 ng / mL 
while the concentration of our variants was on average of 1000 ng / mL. To ensure the low protein 
concentration was not a consequence of sPD1HAC DNA degradation, pcDNA.sPD1HAC was tested using 
gel electrophoresis alongside pcDNA.sPD1WT. No signs of DNA degradation were visible on the gel - 
typically characterised by a smeared appearance, instead DNA presented itself as a solid band on the 
gel (Figure 3.6.1). To further confirm DNA integrity the sPD1HAC DNA was sequenced and analysed to 
confirm the presence of all introduced mutations and to verify that no random undesired mutations 
have emerged. The amino acid sequence is shown (Figure 3.6.1) aligned with sPD1WT sequence with the 
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mutations highlighted. The 10 mutations present are all the introduced mutations to increase binding 
affinity to PD-L1 and no additional random mutations emerged confirming DNA integrity. Therefore, 




Figure 3.6.1. Analysis of sPD1HAC DNA integrity with the amino acid sequencing results of sPD1HAC shown aligned 
with sPD1WT sequence. A) Gel image of pcDNA.sPD1HAC alongside pcDNA.sPD1WT to detect DNA degradation. B) 
Amino acid sequence of sPD1HAC (black) aligned with the sPD1WT (red) amino acid sequence. The amino acid 
sequences were derived from the sequencing results of the respective plasmids. The mutations within the sPD1HAC 







To examine whether the levels of the sPD1HAC could be increased, we expressed sPD1HAC as a fusion 
protein with IgG-Fc. For this the sPD1HAC fragment was engineered onto an IgG1-based expression 
plasmid (pFUSE-hIgG1-fC1). This plasmid generates Fc-fusion proteins that express the Fc region (CH2 
and CH3 domains) of the human IgG1 heavy chain and the hinge region. The sPD1HAC fragment was 
amplified from the pcDNA.sPD1HAC expression plasmid by PCR introducing EcoRI and BglII restriction 
sites and inserted into the pFUSE-hIgG1-Fc vector, which contains the same restriction in its multi-
cloning site. In this way, a final pFUSE.sPD1 expression construct was generated with the DNA map 
shown in Figure 3.6.2. 
 
 
Figure 3.6.2. A map of the recombinant pFUSE.sPD1 expression construct with the key features shown. The 
pFUSE.sPD1 construct is 4674 bp in size. It contains an EF-1α core promoter (dark green) which drives strong gene 
expression, a gene for Zeocin resistance (blue) to allow selection of positive bacterial clones and a region coding 
for the human IgG1 region (dark red). The sPD1 gene is inserted at the EcoRI and bglII cleavage sites and is located 





A pFUSE.sPD1HAC expression construct was generated as well as pFUSE.sPD1WT and pFUSE.sPD1TETR. 
These constructs were used to transfect Human Embryonic Kidney Cells 293 cells (HEK293) cells to test 
protein secretion in human cells and the protein concentration was measured via ELISA (Figure 3.6.3). 
The control sample used here is a supernatant from non-transfected HEK293 cells, which tested 
negative for sPD1 expression. The results show significantly higher sPD1 protein concentrations in all 
sPD1 variants when the protein is expressed as an IgG-Fc fusion protein, with pcDNA.sPD1HAC having a 
significantly lower expression rate than both pcDNA.sPD1WT and pcDNA.sPD1TETR. The concentration of 
pcDNA.sPD1WT and pcDNA.sPD1TETR proteins is 120 ng / mL and 142 ng / mL respectively while the 
concentration of pcDNA.sPD1HAC is 24 ng / mL. The concentration of pFUSE.sPD1HAC is significantly 
higher at 2127 ng / mL. pFUSE.sPD1WT and pFUSE.sPD1TETR protein concentrations are 1904 ng / mL and 
552 ng / mL respectively. The results suggest that the tetramerization site interferes with protein 
production when sPD1TETR is engineered into the pFUSE-hIgG1-Fc expression vector, but not when in 







Figure 3.6.3 Comparison of protein expression of IgG1-Fc Fusion and non-Fusion sPD1 variants in HEK293 
supernatants. HEK293 cells were transfected with sPD1WT, sPD1HAC and sPD1TETR variants cloned into pFUSE-hIgG1-
Fc or pcDNA3 plasmids to produce IgG1-Fc Fusion and non-fusion proteins, respectively. The concentration of the 
sPD1 variants in the supernatant was analysed using the ELISA method. A) Comparison of protein expression of 
the IgG1 fusion and non-fusion sPD1 variants. B) Comparison of protein expression of non-fusion sPD1WT, sPD1HAC 
and sPD1TETR variants. C) Schematics visualising the structure of the non-fusion sDPD1 variants and their molecular 
weights. D) Schematics visualising the structure of IgG1-Fusion sPD1 variants and their molecular weights. The 
CH2 and CH3 groups of the FC region are shown. All data is expressed as mean ± SE of duplicate wells and are 
representative of three independent experiments.   
 
To detect any variances in pcDNA.sPD1WT and pFUSE.sPD1WT binding to PD-L1 the proteins were tested 
in a solid-phase protein competition assay. The signal from the pcDNA.sPD1WT sample was set as 100% 
rPD1 binding. The results (Figure 3.6.4) show no significant difference in the binding of sPD1WT to PD-
L1 when expressed on different vectors. This suggests that while IgG1-Fc gives sPD1 variants better 
stability, it does not interfere with binding and competition. sPD1WT and sPD1HAC IgG1-Fc fusion proteins 




Figure 3.6.4. Comparison of recombinant PD1 (rPD1) binding to PD-L1 in samples with sPD1WT and sPD1WT.IgG as 
competitors. A microplate was coated with 100 ng of PD-L1 per well. 50 ng of each sPD1 variant was incubated 
with 50 ng of rPD1 in a solid-phase protein competition assay. Competition of pFUSE.sPD1WT is shown as 
percentage of competition of pcDNA.sPD1WT. Data is expressed as mean ± SE of duplicate wells and are 
representative of three independent experiments.  
  
3.7. Protein affinity testing to PD-L1 of the sPD1HAC protein 
sPD1HAC.IgG was tested in a solid-phase protein competition assay to analyse the binding to PD-L1. 50 
ng of rPD1 was incubated with CHO supernatant containing sPD1HAC in the amounts of 20, 10 and 1 ng 
to observe protein competition rates. The results (Figure 3.7.1) revealed sPD1HAC.IgG to be a strong 
inhibitor of the PD1/PD-L1 signalling interaction. 20 and 10 ng of sPD1HAC.IgG were sufficient to 
completely outcompete 50 ng of rPD1. Even at quantities of 1 ng sPD1HAC.IgG can still outcompete 97% 
of rPD1 binding. These results reveal that the binding of sPD1HAC.IgG to PD-L1 is approximately 50 times 
























Figure 3.7.1 Competition assay testing the binding of sPD1HAC.IgG and sPD1WT.IgG at decreasing concentrations 
to PD-L1 against 50 ng of recombinant PD1 (rPD1). A microplate with 100 ng of PD-L1 attached to the surface of 
each well was treated with 20, 10 or 1 ng of sPD1WT.IgG and sPD1HAC.IgG protein variants with 50 ng of rPD1. 
Data is expressed as mean ± SE of duplicate wells and are representative of three independent experiments.  
 
The binding of sPD1HAC is a magnitude stronger than other sPD1 variants tested which led to the 
question if the stronger binding is specific for PD-L1 or if the protein is ‘adhesive’ in nature. To test this, 
a microplate was coated with PD-L1, PD-L2 and an unrelated protein – Glutathione S-transferase (GST) 
and incubated with 20 ng of either sPD1WT or sPD1HAC. Bound protein was detected with a PD1 detection 
antibody and quantified via an enzyme-linked reaction. The results revealed that sPD1HAC only binds to 
PD-L1 and does not bind to PD-L2 or GST (Figure 3.7.2). These results demonstrate that sPD1HAC binds 




Figure 3.7.2. Analysis of sPD1HAC.IgG binding to PD-L1, PD-L2 and Glutathione S-transferase (GST). 20 ng of 
sPD1HAC.IgG was added to wells with PD-L1 (blue), PD-L2 (red) and GST (green) immobilised to the surface. 
Bound sPD1HAC was detected using an anti-PD1 antibody and quantified via an enzyme-linked reaction. Coated 
wells incubated without sPD1HAC.IgG were used as controls. All data are expressed as mean ± SE of duplicate 
wells and are representative of three independent experiments.  
 
 
To determine the minimum quantity of sPD1HAC.IgG needed to maintain the competitive effect on rPD1, 
CHO supernatant containing sPD1HAC.IgG in the amounts of 20 – 0.001 ng was incubated with 50 ng of 
rPD1. The results (Figure 3.7.3) show that even at a quantity of 0.1 ng sPD1HAC.IgG can exert competitive 
binding effects. In this condition 16% less rPD1 binds to PD-L1 compared to the control sample. Binding 
of sPD1HAC.IgG is no longer detected with 0.01 ng protein in the sample. These results display that even 





Figure 3.7.3. Determination of the minimum quantity of sPD1HAC.IgG required to outcompete 50 ng of 
recombinant PD1 (rPD1). A microplate with 100 ng of PD-L1 attached to the surface of each well was treated 
with sPD1HAC.IgG quantities ranging from 20 ng to 0.001 ng together with 50 ng of rPD1. All data are expressed 
as mean ± SE of duplicate wells and are representative of three independent experiments.  
 
To ensure that sPD1HAC.IgG does not denature or lose function in an acidic environment which might 
exist inside of tumours, a solid-phase competition assay was conducted in buffers with pH values of 6.5 
and 7.5. Cell supernatant containing 0.1 ng of sPD1HAC.IgG was incubated with 20 ng of rPD1. For 
comparison, a control sample was used which consisted of supernatant from non-transfected cells. The 
results (Figure 3.7.4) reveal that sPD1HAC.IgG binding to PD-L1 is not affected by a lowering of pH - 0.1 
ng of sPD1HAC.IgG outcompetes approximately 19% of rPD1 at pH 6.5 and 28% at pH 7.5. These results 




Figure 3.7.4 sPD1HAC.IgG binding to PD-L1 in a solid-phase protein competition assay at pH values of 6.5 and 7.5. 
A microplate with 100 ng of PD-L1 attached to the surface of each well was treated with 0.1ng sPD1HAC.IgG and 
20ng rPD1. The control sample contains supernatant from non-transfected cells. All data is expressed as mean ± 
SE of duplicate wells and are representative of two independent experiments.  
 
3.8. Analysis of sPD1HAC.IgG binding to PD-L1 in a cellular competition assay 
To ensure sPD1HAC.IgG exhibits the same binding affinity to a membrane-bound PD-L1 as to plate-bound 
PD-L1, protein binding was tested in a cellular competition assay. The sPD1HAC.IgG test sample consisted 
of PD-L1-positive PancTuI cells, which were incubated with 50 ng of sPD1HAC.IgG and 50 ng of rPD1. The 
results (Figure 3.8.1) show a drastic reduction in rPD1 binding to PD-L1 in the sPD1HAC.IgG test sample 
compared to the control sample where no sPD1HAC.IgG is present. The test sample and isotype sample 
both exhibit the same signal indicating that sPD1HAC.IgG is completely outcompeting the rPD1 binding 
in the test sample.  These results suggest that sPD1HAC.IgG will be effective in blocking the PD-L1 signal 
























Figure 3.8.1. Flow cytometry results showing competitive binding of recombinant PD1 (rPD1) and sPD1HAC to PD-
L1 on the surface of PancTuI cells. PancTuI cells were stimulated with IFN-γ to induce PD-L1 expression on their 
surface. The binding affinity of sPD1HAC to PD-L1 was then analysed in a competition assay where sPD1HAC 
competes for the binding site of PD-L1 on the surface of PancTuI cells with rPD1– a commercial recombinant PD1 
protein engineered with a biotin tag. First the full binding capacity of rPD1 was tested (blue) – 2x106 PancTuI cells 
were coated with 50 ng of rPD1 and the bound rPD1 was detected with streptavidin-PE conjugate and the signal 
intensity was measured via flow cytometry. To observe protein competition (green), 2x106 PancTuI cells were 
incubated with 50 ng of sPD1HAC and 50 ng of rPD1. Unbound protein was washed away and PancTuI cells were 
incubated with a streptavidin-PE conjugate and the signal intensity was measured. A negative control to detect 
background radiation (grey) was tested by incubating 2x106 PancTuI cells with the streptavidin-PE conjugate.  
 
3.9. sPD1HAC.IgG adenoviral vector generation 
The affinity of sPD1HAC.IgG to PD-L1 is very strong, even at small concentrations. It is much more 
effective than any of the other sPD1 variants at inhibiting the binding between rPD1 and PD-L1 and was 
selected as a suitable candidate for further studies. The sPD1HAC.IgG fragment was cloned into an 
adenoviral expression vector - pAd/CMV/V5-DEST. With this plasmid an adenoviral vector 
(Ad.CMV.sPD1HAC) was produced and purified by a company (Vector Biolabs) which was then used to 




Figure 3.9.1. Plasmid map of the Ad.CMV.sPD1HAC construct. A plasmid map showing a recombinant 35,773 bp 
construct containing the sPD1HAC.IgG fragment (red) within a pAd/CMV/V5-DEST adenoviral expression vector. 
The vector contains an Ampicillin resistance gene (green) to allow selection, and a CMV promoter and enhancer 
(yellow) required for transient expression of the transgene.  
 
 The supernatant of the MSCs was harvested and analysed via ELISA (Figure 3.9.2). The results revealed 
that the sPD1HAC.IgG protein was successfully produced and secreted by MSCs at the concentration of 
6.55 ng / mL. The control used alongside the sample is supernatant from MSCs transduced with a 





Figure 3.9.2. ELISA results showing protein concentration of sPD1HAC.IgG secreted by mesenchymal stem cells 
(MSCs). A recombinant Ad.CMV.sPD1HAC vector was used to transduce MSCs. The supernatant was harvested, 
and protein expression was analysed via ELISA. The negative control is a sample of MSC supernatant from cells 
transfected with a control vector. Data is expressed as mean ± SE of triplicate wells and are representative of 
two independent experiments.  
 
The generation of sPD1HAC.IgG -expressing MSCs was successful, and these cells can be used in future 
in vivo experiments to deliver sPD1HAC to tumours to block the PD1/PD-L1 pathway and act as an 








































In this study, sPD1 variants with stronger binding characteristics to PD-L1 than the wild-type sPD1 were 
engineered. They were produced in CHO cells and successfully secreted into the medium. After having 
confirmed protein expression and measured protein concentration, they were analysed in vitro with 
the use of solid-phase and live pancreatic cell assays to determine the effectiveness of the variants at 
outcompeting the sPD1WT binding to PD-L1. Protein variants were generated via MMBSA computational 
modelling studies and one variant was found through a literature search. The sPD1 variants designed 
via the MMPBSA computational molecular method showed modestly increased binding affinities. While 
the single point mutations led to a change in binding properties of sPD1 variant proteins, their affinity 
was not improved enough for them to be deemed effective as an anti-PD-L1 therapeutic. The 
sPD1HAC.IgG variant which contains mutations identified via directed evolution with yeast-surface 
display by Maute et al (2015) revealed itself to be far more effective. Perhaps the reason for such a 
drastic difference in binding affinities between sPD1HAC.IgG and our variants, is that sPD1HAC.IgG contains 
ten point mutations, while sPD11 and sPD127 only contain one. The stacking of multiple mutations 
considerably increases protein binding.  
The sPD1HAC.IgG variant was found to outcompete sPD1WT 500-fold even at very low concentrations. 
Protein functionality testing revealed that sPD1HAC.IgG binds to PD-L1 specifically and does not bind to 
PD-L2 and unrelated proteins thus posing as a promising candidate for anti- PD-L1 therapy. The 
sPD1HAC.IgG variant was engineered into MSCs and the protein was successfully expressed and secreted 
form these cells too. The engineered MSCs can provide a novel anti- PD-L1 therapeutic for difficult to 
treat cancer types such as pancreatic cancer. 
PD1HAC was generated through a directed evolution with yeast-surface display (Maute et al., 2015). The 
point amino acid substitutions present in the DNA sequence compose of 8 contact residues and 2 core 
residues. This study used plasmon resonance to reveal sPD1HAC has a 15,000-40,000-fold increase in 
affinity for PD-L1 compared to the wild-type. Molecular dynamics of the structure of the PD1HAC /PD-L1 
complex show the mechanisms by which the point mutations enhance binding affinity (Pascolutti, 
2016). The complex has close resemblance to the structure of wild-type human PD1/PD-L1 complex, 
with a few key changes. PD1HAC engages in a more extensive polar network with PD-L1, which is likely 
contributing to the higher affinity of the protein. The polar interactions in the PD1HAC mutant also show 
greater conformational stability than in the wild-type variant. The mutations cause formations of new 
hydrogen bonds and salt bridges between the PD1HAC and PD-L1. Maute and colleagues tested PD1HAC 
functionality by fusing it to a dimeric CH3 domain of a human IgG1 to create a HAC ‘microbody’. It was 
59 
 
tested in in vivo studies in murine models of colon cancer alongside an anti-PD1 antibody to analyse 
PD-L1 binding and tumour penetrance. In PD-L1 positive tumours there was clear binding of both PD1HAC 
and an anti-PD1 antibody, however in very different distributions. The antibody signal was mainly 
constrained to the peripheral regions of the tumour while the staining for PD1HAC was widespread, 
confirming improved tissue penetrance. Tumour-size was significantly reduced with the use of PD1HAC 
in comparison to antibody injection. More so, there is supporting evidence that a sPD1HAC.IgG protein 
variant would be more effective than an antibody in antagonizing the PD1/PD-L1 pathway in vivo. Mice 
injected with anti-mouse PD-L1 antibody exhibited a 15% decrease in circulating peripheral blood CD8+ 
T cells (Maute et al., 2015) – an effect that was not visible after administration with PD1HAC.  
In our study, instead of a microbody, the PD1HAC protein was engineered as a soluble IgG1-Fc fusion 
protein. We found that the IgG1-Fc significantly increases the stability of the protein and leads to 
increased protein secretion while conferring no negative effects to protein functionality. The IgG1-Fc 
group is known to allow easier protein expression and can improve the solubility and stability of the 
fused partner molecule both in vitro and in vivo as well as conferring several other beneficial biological 
and pharmacological properties to proteins (Czajkowsky et al., 2012). Notably, the presence of the Fc 
domain extends the plasma half-life of protein thus prolonging therapeutic activity. This is due to the 
reduced renal filtration and elimination rate of larger molecules (Kontermann, 2011) and the Fc domain 
interacting with neonatal FC-receptor (FcRn) in a pH-dependant manner. This prevents the protein from 
being degraded in endosomes and instead allows it to be released back into circulation (Roopenian and 
Akilesh, 2007). Through the binding of Fc to its receptor Fc-gamma receptor (FcγR), immune system 
cells expressing FcγRs are recruited and activated, triggering antibody-dependant cell-mediated 
cytotoxicity (ADCC). ADCC destroys and clears target cells (including tumour cells) via the secretion of 
various substances (perforin, granzyme, TNF) that mediate target cell destruction (Wang et al., 2015). 
In addition to this, Fc binding to the serum complement molecule (C1q) initiates complement-
dependant cytotoxicity (CDC) by initiating the assembly of a membrane attack complex (Meyer et al., 
2014). Out of the four IgG subtypes, IgG1 has the highest affinity to FcyRs and is one of the most 
cytotoxic IgG groups (Bruhns et al., 2009). These features make IgG1-Fc desirable in oncological 
therapies which selectively target tumour cells for destruction and therefore may increase the 
effectiveness of sPD1HAC as a therapeutic.  
Based on the recent evidence that PD-L1 exists in a dimeric state (Lin et al., 2008; Chen et al., 2010), an 
sPD1 tetramerisation variant (sPD1TETR) was produced and analysed to determine improved binding 
abilities. Solid-phase analyses revealed that sPD1TETR possesses slightly stronger binding characteristics 
to PD-L1 in comparison to sPD1WT. These results may support the hypothesis that PD-L1 interacts in a 
dimeric manner and sPD1TETR may be decreasing the off-rate of the reaction by promoting dimerization 
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by decreasing the entropic penalty compared to when monomeric sPD1 proteins are distributed 
randomly. Our results show that in non-IgG-Fc fusion sPD1 variants introduction of a tetramerisation 
site does not interfere with protein production or secretion and therefore tetramerisation does not 
seem to destabilise the protein. However, the combination of the IgG-Fc domain with a tetramerisation 
domain results in significantly decreased protein concentration in the supernatant. This is likely due to 
the fact that the CH3 domains within the Fc interact with each other to form homodimers resulting in 
dimerization of Fc (Yu et al., 2017). The Fc dimerization site and introduced p53 tetramerisation site 
likely combine to produce a protein aggregate with decreased stability. Due to this it is unlikely that an 
sPD1HAC/TETR.IgG mutant would have improved therapeutic functionality as its potentially higher binding 
activity is compromised by the lower expression levels.   
Protein binding analyses show that at pH values of 6.5 and 7.5 sPD1HAC.IgG maintains a comparable 
binding affinity to PD-L1. Tumour microenvironment pH values can range from 5.5 – 7 (Justus et al., 
2013), so it is vital that sPD1HAC.IgG can maintain its function in such conditions. Our results did not 
show any evidence of pH-dependent affinity in sPD1HAC – a contrasting result to Pascolutti et al (2016) 
who reported pseudo-irreversible binding to PD-L1 in low pH conditions. They found that at a pH of 6.5 
the affinity to PD1 increased 100-fold compared to a basic environment and the interaction became so 
strong at pH 5.5, it no longer showed any detectable dissociation in a 600 second timeframe. Perhaps 
the reason these effects were not observed in our study is due to the editing of PD1HAC into a soluble, 
secreted protein which alters its structure in such a way that limits the pH effects. Another explanation 
for the discrepancy in the results may be the difference in the nature of the IgG molecule fused to the 
protein. The sPD1HAC.IgG protein contains both CH2 and CH3 domains of the human heavy chain and 
hinge region. Instead, in the Pascolutti study PD1HAC is fused only to a dimeric CH3 domain. The study 
states that lower pH conditions stabilise the PD1HAC structure and in turn increase binding affinity of 
PD1HAC to PD-L1. It has been observed that CH2 domain exerts a certain level of stability to proteins and 
the presence of this domain in our sPD1HAC.IgG variant may already exert a degree of protein 
stabilization to the protein; perhaps in such a way that limits pH-dependant stabilisation. PD1HAC was 
produced in insect cells while we produced the sPD1HAC.IgG variant in mammalian cells. One of the main 
differences in the two systems, is that insect cells are unable to produce complex, terminally sialylated 
N-glycans such as those produced by mammalian cells. These side-chains are instead replaced by 
paucimannosidic N-glycans, which are not found in mammalian cells (Shi and Jarvis., 2007). These slight 
changes in the modifications of the protein may be generating a protein surface that is affected 
differently by pH variations.  
The inhibitory signals transduced by PD1 in T cells have been well characterised, however the activities 
of PD-L1 have been less so. Recent hypothesis suggests that PD-L1 can propagate signals in the cell on 
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which it is expressed (Lecis et al., 2019). This reverse signalling is not very well defined; however, 
research suggests that it can deliver pro-proliferative and protective signals to the tumour (Jalali et al., 
2019). This poses a challenge in anti-PD-L1 therapies as the prolonged binding to PD-L1 by high-affinity 
therapeutics may inadvertently trigger pro-tumour signalling in cancer cells, thus affecting the clinical 
outcome of the therapy. There is evidence to show that in the case of neoplastic cells, the short intra-
cytoplasmic tail of PD-L1 contains signal transduction motifs that mediates cell protection through a 
STAT3/caspase-7-mediated pathway (Gato-Cañas et al., 2017).  This protective function ultimately 
contributes to tumour growth and progression. One study found that PD-L1 signalling promotes the 
EMT phenotype in human oesophageal cancer as well as playing roles in viability and migration (Chen 
et al., 2017). Another study demonstrated an association of PD-L1 with a stem-like phenotype and using 
PD-L1 knockout experiments found that PD-L1 is involved in maintaining stemness markers (Oct-4, 
Nanog, BMI1). Down-regulation of PD-L1 caused a reduction in the self-renewal capacity of breast 
cancer stem cells in both in vitro and in vivo (Almozyan et al., 2017). Antagonising PD-L1 engagement 
with an antibody in classical Hodgkin lymphoma cells resulted in increased proliferation and survival of 
cells and reduced apoptosis, likely through the activation of the MAPK pathway (Jalali et al., 2019). This 
finding highlights the importance of the need to characterise the mechanisms of PD-L1 signalling and 
its potential implications in therapy. It is crucial we monitor sPD1HAC.IgG binding in pancreatic cancer 
cells to detect the extent, if any of the pro-proliferative signalling from PD-L1 as not to accelerate 
tumour growth. 
In this study we successfully generated MSCs that secrete the sPD1HAC.IgG protein, revealing a promising 
new method of targeting the PD1/PD-L1 pathway in pancreatic cancer. It must be noted however, that 
the expression of sPD1HAC.IgG is significantly lower in MSCs than in the HEK293A cells and CHO cells. 
Future studies should attempt to increase the expression of sPD1HAC.IgG in MSCs to maximise clinical 
potency. Although clinical trials demonstrate that MSC injection in high doses is safe (Lalu et al., 2016); 
systemic infusion of MSCs for therapeutic applications requires efficient migration and homing to the 
target tumour and this process is inefficient. There is abundant evidence of MSC homing, however only 
a small percentage of systematically administered MSCs actually reach the target tissue – typically less 
than 1% (Zhang et al., 2007). After injection, MSCs appear to be cleared and trapped in the lungs, 
compromising homing to target tissues. It also appears that MSCs downregulate the expression of 
homing molecules during in vitro expansion (Rombouts and Ploemacher, 2003). There is a lot of interest 
in current research to increase the homing efficacy of MSCs; the strategies involve specific cell 
preconditioning and modification of culture conditions. For example, an important homing molecule 
on the cell surface – CXCR4 can be increased by the addition of cytokines or cytokine cocktails to the 
culture medium during MSC expansion. Exposure to flt3 ligand, stem cell factor (SCF), IL-3, IL-6 and HGF 
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was found to increase both the intracellular and membrane expression of CXCR4 on cultured MSCs (Shi 
et al., 2007). However, the degree of improvement in homing efficiency that these methods provide is 
still unclear and MSCs should be engineered to be as efficient as possible in providing the drug load.  
These cells can be used in future in vivo assays to determine the effectiveness MSC therapy at delivering 
an anti-PD-L1 therapeutic agent to pancreatic cancer. The ability of MSCs to accumulate at tumour sites 
is indeed an attractive feature for directed cancer therapy, however MSCs are not inert vectors and 
have their own properties that can affect tumour growth. Current literature is divided on the effects of 
MSCs on cancer growth, with research indicating MSCs can exert both pro-tumour and anti-tumour 
effects. One important feature of MSCs that needs to be considered in the context of cancer 
immunotherapy, is the profound immunosuppressive effects they possess. Numerous studies 
converged on the findings that MSCs contribute to cancer pathogenesis via the release of inflammatory 
factors which promote immunosuppressive effects. One study found that human MSCs exert 
immunosuppressive effects through the production of indoleamine 2,3-dioxygenase (IDO) (Ling et al., 
2015). These IDO-expressing MSCs were capable of supressing T cell proliferation in vitro and 
dramatically reduced both tumour-infiltrating CD8+ T cells and B cells. Another study revealed that 
MSCs isolated from gastric tumours mediate cancer progression through the secretion of IL-8 – a pro-
inflammatory chemokine involved in the recruitment of leukocytes (Li et al., 2015). Leukocytes such as 
macrophages and neutrophils are known to be involved in cancer initiation and progression (Guo et al., 
2017, Powell et al., 2018). MSCs can also secrete TGFβ which can promote macrophage infiltration at 
the tumour site and facilitates tumour escape from immune surveillance. The ability of MSCs to create 
an immunosuppressive environment is unfavourable in cancer checkpoint inhibition therapy as it can 
negate or reduce the effects of delivered sPD1 and limit overall therapeutic outcome.   
Compelling evidence also points to the role of MSCs in tumour angiogenesis. For instance, bone-
marrow derived MSCs were found to increase the expression of angiogenic factors (TGFβ, VEGF and IL-
6) which contribute to tumour vascularization and growth (Zhang et al., 2013). A correlation between 
expression of TGFβ1 and higher microvessel density was observed in hepatocellular carcinomas in mice 
that received intravenous injections of human MSCs (Li et al., 2016). Another issue with the use of MSCs 
is their potential to promote metastasis. MSCs can induce cancer cell distribution in tumours that would 
not normally form metastatic lesions, however MSCs do not further increase metastasis in tumours 
with a high metastatic potential (Albarenque, 2011). PDAC has an unusually high tendency for 
metastasis, and it is therefore likely that MSCs introduction would not further increase the metastatic 
potential. On top of this, MSCs can differentiate into cancer-associated fibroblasts (CAFs) due to soluble 
factors secreted from cancer cells. CAFs contribute to tumour progression due to their active secretome 
which includes immune-modulating agents (CXCL12, GM-CSF), pro-angiogenic factors (VEGF, TGFβ, 
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PDGF), pro-survival factors (Hepatocyte GF, Insulin-like GF, IL6), and extracellular matrix modulators 
(MMP, Tissue Inhibitor of Metalloproteinases) among others (Kalluri, 2016). The aforementioned 
factors have the potential to exacerbate tumour growth and could lead to an adverse clinical response. 
The goal is to one day re-engineer MSCs and develop safer cells which lack the expression of pro-tumour 
factors for a safer treatment of cancer.  
Interestingly recent research indicates that MSCs may promote apoptosis and supress growth of glioma 
cells through downregulation of the PI3K/AKT signalling pathway (Lu et al., 2019). They found that 
treatment with human bone-marrow derived MSCs could supress phosphorylation of PI3K and AKT in 
U251 cells. This pathway is related to advancement of cell proliferation, suppression of apoptosis, 
change in cell cycle distribution, promotion of invasion, and induction of EMT in most tumour cells. In 
pancreatic cancer cells, downregulation of the PI3K/Akt pathway induced cell cycle apoptosis and G1 
phase cell cycle arrest and supressed EMT (Xu et al., 2014). The PI3K/Akt pathway is one of the signalling 
cascades inhibited by PD1 and is one of the targets for sPD1HAC.IgG. MSC-induced downregulation of 
this pathway could enhance the therapeutic effects of sPD1HAC.IgG and provide a better overall clinical 
outcome.  
Overall, while MSC-based drug delivery is extremely promising, a number of issues have to be 
addressed. Notwithstanding MSCs have the advantage that they would act as a drug depot within the 
tumour site and through a continuous release of sPD1HAC.IgG would extend the time frame of 
sufficiently high drug concentration to exert pharmacological activity. In this way renal clearance is 
further overcome by the constant release of the protein into circulation. However, due to the 




In this study we generated engineered MSCs which successfully produce and secrete a soluble, high-
affinity PD1 protein variant (sPD1HAC.IgG). The sPD1HAC.IgG exhibits success in antagonising the PD1/PD-
L1 pathway in vitro in solid-phase and live pancreatic cell assays. The MSCs offer a novel delivery vector 
to transport this immune-therapeutic into pancreatic cancer and has the potential to overcome current 
challenges with drug delivery into the pancreatic microenvironment. Despite the great promise of using 
MSCs to target cancers, they are associated with several unfavourable biological side effects and should 
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